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Abstract
TARGETING APOPTOTIC PATHWAYS TO OVERCOME DRUG RESISTANCE IN ACUTE
MYELOID LEUKEMIA

Rongqing Pan, M.S.
Supervisory Professor: Michael Andreeeff, M.D., Ph.D.

Evasion of apoptosis is integral to tumorigenesis and drug resistance. BCL-2 and
p53 proteins represent two focal nodes in convergent apoptosis signaling. Upregulation
of anti-apoptotic BCL-2 family members and inactivation of p53 functions are two
canonical approaches exploited by cancer cells to escape apoptosis. In the current
study, we find that BCL-2 protein is highly expressed in acute myeloid leukemia (AML)
cells. BCL-2–specific inhibitor ABT-199 potently induces mitochondrial apoptosis in
AML cells and effectively kills AML stem/progenitor cells. Our biomarker studies
demonstrate that both BH3 profiling and the expression profiling of BCL-2 proteins may
serve as predictive biomarkers for the efficacy of ABT-199. Despite the initial success,
we find that MCL-1 protein renders cancer cells resistant to ABT-199. Next we
investigated whether p53 activation could overcome MCL-1–mediated resistance to
BCL-2 inhibitor ABT-199. We demonstrate that p53 activation by MDM2 inhibitor
RG7388 effectively overcomes the acquired or inherent resistance to ABT-199 both in
vitro and in vivo. Mechanistic studies indicate that ABT-199 induces stabilizing
phosphorylation of MCL-1. Surprisingly, p53 activation mediates the conversion from
stabilized MCL-1 to destabilized MCL-1. Further mechanistic studies demonstrate that
p53 activation inhibits N-Ras/Raf/MEK/ERK signaling and releases GSK3 activity to
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modulate MCL-1 phosphorylation and promote Mcl-1 degradation. Additionally, p53
activation also induces pro-apoptotic proteins such as PUMA and BAX to counteract
MCL-1, thus overcoming Mcl-1 mediated resistance at multiple levels. During the
course of this study, we find that AML cells resistant to BCL-2 inhibition may also be
resistant to p53 activation. We demonstrate that p53-induced p21Cip1 protein confer
tumor resistance by promoting reversible G1 arrest. Importantly, BCL-2 inhibition
switches the outcomes of p53 activation from pro-survival G1 arrest to apoptosis, thus
overcoming AML resistance to p53 activation. The combination of BCL-2 inhibition and
p53 induction markedly prolongs survival in three resistant mouse models of AML.
These results collectively indicate that p53 activation and BCL-2 inhibition reciprocally
overcome apoptosis resistance to either strategy alone. Our study provides novel
mechanistic insights into the mechanisms of apoptosis resistance and forms the
concept for an international phase II trial in AML.
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1.1 Overview
Drug resistance is always a potential concern with targeted therapeutics. Most
targeted compounds focus on upstream nodes of cancer signaling pathways. Although
the initial response might be promising, acquired resistance is often inevitable due to
various compensatory mechanisms mediated by complex cancer signaling networks1-3.
For most cancer treatments, including chemotherapy, radiotherapy, and targeted
therapies, induction of apoptosis represents the principal mechanism by which
malignant cells are eliminated4-6. Therefore, targeting the downstream apoptosis
machinery appears to be a promising strategy since it directly elicits cell death and
possibly minimizes the development of drug resistance. p53 and BCL-2 family proteins
are central regulators of the apoptosis machinery. Upregulation of anti-apoptotic BCL-2
family proteins and inactivation of p53 are two canonical approaches exploited by
cancer cells to escape apoptosis5,7-9. This thesis is composed of two interrelated
projects to target the mitochondrial apoptosis pathway, by inhibiting BCL-2 and
activating p53, to induce apoptotic cell death and to overcome drug resistance of AML
cells.
In the first project (Chapter 2), we found that BCL-2 protein, a key regulator of the
mitochondrial apoptosis pathway, is highly expressed in AML. The advent of ABT-199,
a selective and potent BCL-2 inhibitor, allows us to study whether BCL-2 inhibition
could effectively induce mitochondrial apoptosis in vitro and in pre-clinical mouse
models. In Chapter 2, we tested the hypothesis that AML cells dependent on BCL-2 for
survival would be sensitive to BCL-2 inhibitor ABT-199 and the cellular response to
ABT-199 could be predicted by BH3 profiling. We studied the efficacy and mechanism
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of action of ABT-199 in cell lines, patient samples, and mouse models. We also
evaluated the expression profiling of BCL-2 proteins and BH3 profiling as predictive
biomarkers for cellular response to BCL-2 inhibitor ABT-199. This study has been
translated into a Phase II clinical trial to treat AML patients.
Both the results of the first project as well as the results of the clinical trial indicate
that BCL-2 inhibition by ABT-199 is an effective treatment for AML in preclinical and
clinical settings10,11. However, we found that expression of another anti-apoptotic
protein MCL-1 renders AML cells resistant to ABT-199. In the second project (Chapter
3), we investigated whether p53 activation could overcome MCL-1 mediated resistance
to BCL-2 inhibition and elucidated the detailed mechanisms through which p53
negatively modulated the expression of MCL-1. During the course of this study, we
found that AML p53 wild type cell lines such as OCI-AML3 could also be resistant to
p53 activation. We studied the roles of p21 in mediating apoptosis resistance to p53
activation and tested the hypothesis that BCL-2 inhibition could overcome resistance to
p53 activation by shifting cell response from cell cycle arrest to apoptosis. The
mechanistic and efficacy studies were conducted with three types of drug-resistant
models of AML. Either BCL-2 inhibition or p53 activation alone had limited efficacy in
these three resistant models. However, the combination of the two strategies achieved
remarkable efficacy and markedly prolonged mouse survival. We illustrated, both
mechanistically and therapeutically, BCL-2 inhibition and p53 activation can reciprocally
overcome apoptosis resistance to either strategy alone. Our results provide important
mechanical insights as well as critical preclinical evidence proposing the use of p53–
reactivating compounds in combination with BCL-2 inhibitors in leukemia patients, and
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warrant an international phase II trial to assess the clinical benefit of our proposed
combination therapy.

1.2 Apoptosis Pathways
Apoptosis is a form of highly regulated and programmed cell death that occurs in
multicellular organisms. Apoptosis is evolutionarily conserved from nematodes to
humans and plays essential roles in diverse biological progresses including embryo
development, tissue homeostasis, aging, and immunity9,12. Excessive apoptosis can
cause a number of diseases such as neurodegenerative diseases and ischaemic heart
failure, while inadequate apoptosis leads to diseases associated with excessive
accumulation

of

cells,

such

as

cancer,

autoimmune

disease,

and

chronic

inflammation9,13,14.
Two canonical pathways regulate apoptosis in mammalian cells, namely the
mitochondrial (or intrinsic) pathway and the death receptor-mediated (or extrinsic)
pathway13,15. Mitochondrial apoptosis pathway is tightly regulated by BCL-2 family
proteins. Diverse cytotoxic stimuli such as DNA damage, oncogenic stress, and
developmental cues can shift the balance of BCL-2 family anti-apoptotic and proapoptotic proteins towards the initiation of mitochondrial apoptosis9,16. The subsequent
activation of pro-apoptotic Bax and Bak proteins leads to the release of cytochrome c
and other intermembrane space proteins from the mitochondria. Released cytochrome
c next binds cytosolic Apaf-1 protein to form apoptosome, which in turn cleaves and
activates pro-caspase-9. Activated caspase-9 (one initiator caspase) next cleaves and
activates effector caspases such as caspase-3, -6 and -7 to execute apoptotic cell
death12,13.
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The death receptor-mediated pathway involves binding of extracellular ligands of
TNF family (such as Trail, FasL and TNFα) to transmenbrance death receptors (DR4/5,
Fas and TNFR1, respectively), leading to activation of caspase-813,14. Active caspase-8,
similar as caspase-9, cleaves and activates effector caspases-3 and -7 to induce
extrinsic apoptosis. In addition, caspase-8 also mediates the proteolysis of BID and the
truncated form of BID (tBID) can potentially promote the mitochondrial apoptosis
pathway to amplify the apoptotic response9,13. Numerous studies have shown that
evasion of apoptosis is a hallmark of cancer. Dysregulated apoptotic machinery,
especially the abnormal mitochondrial pathway, is widely associated with tumor
initiation, progression and therapeutic resistance5,9,17,18. For this reason, targeting
apoptotic pathway might be a promising direction for the development of novel cancer
therapies.

1.3 The BCL-2 Protein Family
The BCL-2 family includes at least 16 members of interacting proteins, which
together form a rheostat to regulate mitochondrial outer membrane permeabilization
(MOMP) and regulate mitochondrial apoptosis pathway5,9,17. BCL-2 family protein can
be classified into three functionally different groups. The first group comprises of antiapoptotic proteins including BCL-2, MCL-1, BCL-XL, BFL-1/A1, and BCL-W, all of
which share four BCL-2 homology domains (i.e., BH1, BH2, BH3, and BH4 domains).
These anti-apoptotic proteins can bind and sequester the other two groups of proapoptotic proteins to prevent apoptosis from happening14,17,18. The second group
consists of three proteins, Bax, Bak, and Bok, all of which are multi-domain proapoptotic proteins sharing BH1, BH2 and BH3 domains. When activated, Bax, Bak, and
Bok adopt a pro-death conformation and oligomerize to form channels in the
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mitochondrial outer membranes. As a result, cytochrome c, as well as other
intermembrance space proteins such as Omi and Diablo, will be released from
mitochondria to initiate mitochondrial apoptosis12,19.
Members of the third group are BH3-only pro-apoptotic proteins including Puma,

Bim, Bid, Bad, Noxa, Hrk, Bmf, and Bik. BH3-only proteins, as the name implies, share
only one BCL-2 homology domain BH3. All members in this group are able to bind and
counteract at least one anti-apoptotic protein. For example, Hrk binds BCL-XL; Noxa
binds MCL-1 and BFL-1; Bad or Bmf binds BCL-2, BCL-W and BCL-XL; whereas Puma,
Bid, and Bim bind all five anti-apoptotic BCL-2 proteins14,17. The BH3-only proteins can
be further divided into two subsets: sensitizers (i.e., Bad, Noxa, Hrk, Bmf, and Bik) and
activators (i.e, Bim, Bid, and Puma)20-22. In addition to inhibiting anti-apoptotic members,
BH3-only activator proteins also directly interact with and activate Bax and Bak to
promote their conformational changes and oligomerization to form channels across
mitochondrial outer membrane23,24. BH3-only sensitizers cannot activate Bax and Bak
but instead bind and sequester anti-apoptotic proteins to prevent them from interacting
with Bax, Bak and BH3-only activators. The dynamic interaction of the three groups of
BCL-2 proteins determines the survival or death of cells under various physiological or
pathological stimuli.

1.4 BH3 Mimetics as Cancer Therapeutics
Over the past three decades, research on BCL-2 family proteins and mitochondrial
apoptosis has led to the development of small molecules mimicking the BH3 domains
of BH3-only proteins. This type of compounds, termed as BH3 mimetics, can dock into
the binding grooves of BCL-2 anti-apoptotic proteins, replace and release the
sequestered pro-apoptotic proteins to directly induce mitochondrial apoptosis of cancer
6

cells4,5. ABT-73725 and its orally-bioavailable counterpart ABT-263/navitoclax26
represent a breakthrough in the development of BH3 mimetics9. ABT-737 and ABT-263
have submicromolar affinities for BCL-2, BCL-XL and BCL-W. Although both of the two
BH3 mimetics have shown promising efficacy from bench to bedside studies, on-target
thrombocytopenia caused by BCL-XL inhibition limits the usage and efficacy of ABT263 in the clinical settings5. Recently, Souers, et al. reported the re-engineering of
ABT-263 to generate ABT-199 (venetoclax), a first-in-class BCL-2 specific inhibitor27.
ABT-199 has significantly enhanced avidity and specificity for BCL-2 protein compared
to its predecessors ABT-737 and ABT-26327. ABT-199 has shown potent efficacy
against several cancers, earned several Breakthrough Therapy Designations, and was
recently approved by US FDA for the treatment of chronic lymphocytic leukemia with
chromosomal 17q deletion. Nevertheless, ABT-199, as well as its predecessors ABT737 and ABT-263, binds poorly to MCL-1. Thus, tumor cells expressing high levels of
MCL-1 are usually very resistant to these agents11,28-31. Overexpression of the antiapoptotic BCL-2 proteins, especially MCL-1 and BCL-2, has been widely implicated in
resistance to conventional chemotherapy and novel targeted therapeutics. Therefore,
development of selective and potent BH3 mimetics to inhibit these antiapoptotic
proteins has become a pressing pharmacologic need for treatment of refractory
malignancies.

1.5 MCL-1 as a Cancer Therapeutic Target
MCL-1 amplification and aberrant overexpression have been shown to be one of
the most common genetic aberrations in hematological malignancies and in solid
tumors, including leukemia, lymphoma, multiple myeloma, melanoma, lung, colorectal,
breast, pancreatic, prostate as well as ovarian and cervical cancers 4,9,32. In particular, it
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has been shown that MCL-1 is essential for the survival of AML cells28,33. Gores, et al.
reported that MCL-1 ablation resulted in almost complete loss of viable AML cells in
MCL-1 knockout mouse models28. Furthermore, elevated MCL-1 expression confers
cancer cell resistance to aforementioned BCL-2 inhibitors and a number of widely used
anticancer chemotherapeutics4,9. These facts, collectively, established MCL-1 as one
key target for antitumor therapies.
The advent of BCL-2 inhibitors such as ABT-737 and ABT-199 has had a profound
impact in the field of targeting mitochondrial apoptotic pathways4,5. ABT-199 is currently
intensively investigated as monotherapy or in combination with other therapies in
various cancers. Nevertheless, the development of MCL-1 inhibitors progressed more
slowly and lagged behind, perhaps because MCL-1 binding groove is more rigid than
BCL-2 groove34. As mentioned above, the emerging roles of MCL-1 in tumorigenesis,
tumor progression, and therapeutic resistance make it an important cancer target.
Tremendous efforts have been made towards the development of MCL-1 specific
inhibitors. However, the reported MCL-1 inhibitors, small molecules or stabled peptides,
are still at an early stage and only have moderate affinity for MCL-133. Therefore, highly
potent MCL-1-selective BH3 mimetics have been eagerly awaited, as both tool
compounds and therapeutic agents.

1.6 p53 Protein in Cancer
p53, arguably the most important tumor suppressor gene, was identified by Lionel
Crawford, David Lane, Arnold Levine, and Lloyd Old nearly four decades ago. p53
protein senses DNA damage and other stresses (e.g., oncogene activation, hypoxia,
and nutrient deprivation) and triggers diverse biological responses such as apoptosis,
cell cycle arrest, and senescence35,36. The best-characterized function of p53 is as a
8

transcription factor to induce or repress the expression of many genes and microRNAs.
p53 expression can be regulated at transcriptional, translational and post-translational
modification (PTM) levels25,26. Among them, the regulation of p53 protein stability by
MDM2 is a critical mechanism through which p53 activity is dynamically modulated.
MDM2, an E3 ubiquitin ligase of p53, not only targets p53 for degradation through the
ubiquitin-protesome pathway, but also directly inhibits the transcriptional functions of
p53 by binding to its transcriptional activation domain35,37,38. Notably, p53 also
transcriptionally induces MDM2 mRNA expression, thus creating a negative feedback
loop to control p53 activity39,40.
p53 mutations have long been implicated in carcinogenesis and therapeutic
resistance. In genetic mouse models, p53 deletion leads to the spontaneous
development of tumors, establishing the role of p53 as a tumor suppressor gene. p53 is
also the most frequently mutated gene in human solid tumors, with about half of all
solid tumors carrying p53 mutations8,41,42. Interestingly, p53 mutation is rare in the
majority of hematological malignancies such as AML, MDS, MM, CLL, CML, and
ALL43,44. However, wild type p53 functions can be suppressed by MDM2, which is
frequently overproduced through gene amplification or overexpression in tumors with
wild-type p53. We have reported that MDM2 is highly expressed in most primary AML
samples, and its overexpression is strongly associated with poor prognosis45,46.
A number of strategies have been devised to reactive p53 functions, e.g., using
small molecules to disrupt p53-MDM2 interaction, p53 gene therapies, and designing
drugs to restore the wild type functions of mutant p538,42. The development of Nutlins, a
set of small molecule inhibitors of p53-MDM2 interaction, represents a breakthrough in
this field8,47. To date, a number of pharmaceutical companies have developed their own
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MDM2 small molecule inhibitors and are evaluating these compounds in pre-clinical
studies and in early phase clinical trials. The recently developed RG7388 (abbreviated
here as RG) is a second-generation MDM2 inhibitor with greater potency, selectivity,
and bioavailability compared to its predecessors nutlins48. RG will be used in Chapter 3
to mediated non-genotoxic activation of p53. We first demonstrated that RG could
robustly activate p53 and that RG-induced apoptosis was highly dependent on p53,
indicating that RG can serve as an ideal compound to study p53 activation. Since p53
is also a critical regulator of mitochondrial apoptosis, next we studied whether p53
activation by RG could abrogate MCL-1 mediated resistance to BCL-2 inhibitor ABT199 in several resistance models of AML.

1.7 Acute Myeloid Leukemia and Therapies
Acute myeloid leukemia (AML) is a hematopoietic malignancy characterized by the
rapid accumulation of abnormally differentiated, non-functional myeloid cells49,50. The
current 5-yr survival rate is 26% for AML patients and this disease accounts for over
10,000 deaths per year in US51,52. Acute promyelocytic leukemia (APL) is the M3
subtype of AML and represents 10-12% of all AML cases. Nowadays, APL can be
effectively treated with all-trans retinoic acid (ATRA) and arsenic trioxide (ATO)53. The
long-term cure of APL patients with ATRA and ATO therapy represents the only
therapeutic breakthrough over the past two decades for AML treatment.
Except for APL, current AML treatment relies largely on induction chemotherapy
and bone marrow/stem cell transplantation. Induction therapy with cytarabine and an
anthracycline compound remains a standard of care in AML51. However, most AMLs
develop chemoresistance during the course of treatment and AML patients tend to
relapse after initial response54,55. The fact that only 10-20% of AML patients are cured
10

by chemotherapy highlights the urgent need for novel treatment options. Although bone
marrow transplantation is potentially curative, only 25% of AML patients are eligible for
this therapy and only half of transplanted patients can survive long-term51. The 5-year
survival rate has only marginally increased over the past few decades and 70% of AML
patients still die from this hematological malignancy51,52,56. Consequently, there is a
substantial unmet need for new AML therapeutic regimens.
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2.1 Chapter Introduction
Acute myeloid leukemia is a hematopoietic neoplasia characterized by the rapid,
clonal growth of the myeloid lineage of blood cells. The disease affects approximately
14,000 adults in the United States each year and unfortunately, despite recent
advances in the treatment of AML, 10,400 people die from their disease57. Most AML
patients become resistant to chemotherapy at some point in their course and succumb
to their disease. Therefore, it is necessary to prevent chemo-resistance or enhance
chemo-sensitivity in a selective fashion to lead to a higher cure rate and a lower toxic
burden.
A novel strategy to treat cancer cells is to directly stimulate the mitochondrial
apoptotic pathway in them. ABT-263 (navitoclax), which functions as a small molecule
mimetic of the BH3 domain of the BH3-only sensitizer protein BAD, efficiently binds to
BCL-2, BCL-XL and BCL-W, releasing bound pro-apoptotic proteins and causing
MOMP in BCL-2 dependent cancer cells26. In early clinical trials, navitoclax showed
potency in the treatment of chronic lymphocytic leukemia (CLL) and small-cell lung
cancer30,58. However, treatment with navitoclax causes on-target, dose-limiting
thrombocytopenia because platelets are dependent on BCL-XL for their survival59. The
dose-dependent thrombocytopenia limited navitoclax’s use in many malignancies,
particularly leukemias where patients often present with pre-existing thrombocytopenia.
This prompted the development of ABT-199, a modified BH3-mimetic derivative of
ABT-263 which maintains specificity for BCL-2, but lacks affinity for BCL-XL27. The
remodeled drug has shown cancer killing efficacy in CLL in vivo, myc-driven
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lymphomas in mice and estrogen receptor-positive breast cancer while sparing
platelets27,60,61.
AML bulk and stem cells might be dependent on BCL-2 for survival and BCL-2
inhibition by ABT-737 causes cell death in AML cells29. Importantly, BCL-2 inhibition
relatively spares normal hematopoietic stem cells62,63. Thus, the first goal of the present
study is to evaluate the anti-cancer effects of ABT-199 on AML and compare its
efficacy with ABT-737/ABT-263, drugs that have both shown activity in the ex vivo
treatment of AML cell lines and AML primary patient samples and in human clinical
trials29. The second goal is to determine if BH3-profiling can be used as a tool to predict
cellular response to ABT-199 treatment.
BH3-profiling is a method to determine the mitochondrial priming level of a cell by
exposing cellular mitochondria with standardized amounts of peptides derived from the
BH3 domains of BH3-only proteins and determining the rate of MOMP, as measured by
either cytochrome c release or depolarization across the inner mitochondrial membrane
64.

Previously, we have shown that the priming status of the cell is predictive of the

cell’s chemo-responsiveness in that the more primed the cell is, the more sensitive the
cell is to various chemotherapeutics62,65. Furthermore, BH3-profiling can also identify
anti-apoptotic addictions62,65,66. For instance, the BAD BH3-only peptide binds with high
affinity with BCL-2, BCL-XL and BCL-W, while the HRK BH3 peptide binds with high
affinity only to BCL-XL. Thus, MOMP following BAD peptide incubation suggests an
anti-apoptotic dependency on BCL-2, BCL-XL or BCL-W, while MOMP following HRK
peptide incubation indicated dependency on BCL-XL. Using this tool, we can identify
AML cells which depend on BCL-2 for survival and that are more likely to die following
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BCL-2 inhibition. Thus, we hypothesize that cells that are addicted to BCL-2 for survival
will be sensitive to ABT-199 and that we can predict this response by BH3 profiling.

2.2 Materials and Methods
2.2.1 Cell lines
The AML cell lines were purchased from the American Type Culture Collection
(Manassas, VA) or Deutsche Sammlung von Mikroorganismen und Zellkulturen
(Braunschweig, Germany) or were kindly provided by Dr. James Griffin (Dana-Farber
Cancer Institute, Boston, MA). HL-60 cell lines with stable overexpression of BCL-2 or
BCL-XL, and the control cell line with empty vector, were kindly provided by Dr. Kapil
N. Bhalla (The Methodist Hospital Research Institute, Houston, TX). AML cell lines
were cultured in RPMI 1640 medium supplemented with 10% or 20% fetal bovine
serum, 10mM L-glutamine, 100 U/ml penicillin and 10 mg/ml streptomycin. Cells were
kept at 37°C in a humidified atmosphere of 5% CO2.
2.2.2 Measurement of Apoptosis, Live Cell Number and IC50 Values
Exponentially growing cells were treated with different compounds or dimethyl
sulfoxide (DMSO) as indicated in each figure and figure legend. DMSO served as drug
vehicle and its final concentration was less than 0.1%. After treatment, cells were
collected, stained with Annexin V (AnnV) and propidium iodide (PI; Sigma-Aldrich, St
Louis, MO, USA), and analyzed by flow cytometry. Briefly, cells were washed twice by
centrifugation (1000g, 5 min) with 2 mL AnnV binding buffer (ABB; 10mM HEPES,
140mM NaCl, and 5mM CaCl2 at pH 7.4 ). After washing, cells were resuspended in
0.1 mL ABB containing fluorochrome-conjugated AnnV and incubated in darkness at
room temperature for 15 min. The cells were washed again with 2 mL ABB and then
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resuspended in 0.3 mL ABB. PI was added at a final concentration of 1 μg/mL before
analysis by a Gallios flow cytometer (Beckman Coulter, Indianapolis, IN, USA). To
determine absolute cell number, CountBright Absolute Counting Beads (Life
Technologies, Carlsbad, CA, USA) were also added. Data were analyzed by Kaluza
software version 1.3 (Beckman Coulter). Calcusyn 2.0 software (Biosoft, Great
Shelford, UK) was used to calculate IC50 values and combination index, based on the
absolute number of live cells (i.e., AnnV-/PI-). AnnV-FITC and AnnV-APC were
purchased, respectively, from Roche Applied Sciences (Indianapolis, IN, USA) and BD
Biosciences (San Jose, CA, USA).
2.2.3 Quantitative Western Blot
Cells were subjected to lysis at a density of 1 x 106/50 μL in protein lysis buffer
(0.25 M Tris-HCl, 2% sodium dodecylsulfate, 4% β-mercaptoethanol, 10% glycerol,
0.02% bromophenol blue) supplemented with 1x protease/phosphatase inhibitor
cocktail (#5872, Cell Signaling Technology, Beverly, MA, USA). Cell lysates were then
loaded onto polyacrylamide gels with sodium dodecyl sulfate (Bio-Rad, Hercules, CA,
USA). After electrophoresis, proteins were transferred to polyvinylidene difluoride
membranes. The transblotted membranes were blocked for 1 h and then probed with
appropriate primary antibodies (dilution as recommended by manufacturers) overnight
at 4°C. Next, the membranes were washed three times for a total of 30 min and then
incubated with secondary antibodies in darkness at room temperature for 1 h. After
another three washes, Odyssey infrared imaging system and companion software (LICOR Biosciences, Lincoln, NE, USA) were used to scan immunoblot membranes and
to quantify band intensity according to the manufacturer’s manual. The ratio of band
intensity of BCL-2 proteins relative to that of loading control was normalized to the ratio
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in untreated OCI-AML3 cells. Antibodies used for quantitative Western blot were: BCL2 (#M0887, Dako, Carpinteria, CA), BCL-XL (# 2764, Cell Signaling Technology,
Danvers, MA), MCL-1 (#559027, BD Biosciences, San Diego, CA), α-Tubulin and βActin (loading controls, #T6199 and #A5441, Sigma-Aldrich, St. Louis, MO).
2.2.4 MCL1 Knockdown by Lentiviral shRNA
MCL1 was knocked down by lentiviral transduction using a MCL1-specific shRNA
transfer vector targeting residues 2421-2440 on RefSeq NM_021960.4. Lentivirus was
prepared by co-transfection of HEK293T cells (ATCC) with an equal molar mix of
transfer vector and packaging plasmid (psPAX2 and pMD2.G, Addgene, Cambridge,
MA) using JetPrime transfection reagent as directed by the manufacturer (Polyplus,
Illkirch, France). Fresh lentiviral supernatants were passed through 0.45 μm surfactantfree cellulose acetate membranes; polybrene was added to 8 μg/mL, and the virus
stock was used at once to spinoculate OCI-AML3 cells as described before67. Infected
cells were selected with 0.5 μg/mL puromycin. In parallel, control cells were transduced
using lentivirus delivering a hairpin targeting GFP in pLKO.1 (Addgene). Knockdown
was verified by Western blot analysis.
2.2.5 BH3 Profiling of Cell Lines
AML cell lines were seeded at a density of 4 x 10 5 cells/mL in 10% FBS RPMI
media supplemented with 10 mM L-glutamine, 100 U/ml penicillin and 10 mg/ml
streptomycin 24 h before BH3 profiling. Two million cells of each cell line were pelleted
at 400 xg for 5 minutes at RT and resuspended in 2 mL DTEB (135 mM Trehalose, 10
mM HEPES-KOH, 0.1% w/v BSA, 20 uM EDTA, 20 uM EGTA, 50 mM KCl, 5 mM
succinate, final pH 7.4). Cell lines were profiled by using the plate-based JC-1 BH3
profiling assay previously described62.Cells were permeabilized with digitonin, exposed
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to BH3 peptides, and mitochondrial transmembrane potential loss was monitoredusing
the ratiometric dye JC-1.
2.2.6 Isolation and Treatment of Primary AML Cells
Primary AML cells were obtained by informed consent from the Dana-Farber
Cancer Institute, Leukemia Group, the Pasquarello Tissue Bank at the Dana-Farber
Cancer Institute, the University of Texas MD Anderson Cancer Center, Leukemia
Tissue Bank Shared Resource from the Ohio State University Comprehensive Cancer
Center and the Germany-Austrian Study Group according to protocols approved by the
Institute’s Institutional Review Board. Samples were Ficoll purified, used immediately or
viably frozen in 90% FBS/10% DMSO. Fresh (Figures 2.4A, 2.4D and 2.4E) or thawed
(Figure 2.4B) mononuclear cells were resuspended in culture medium. Cells were
treated with ABT-199, ABT-263 or ABT-737 for appropriate time. Cells were then
washed with PBS and resuspended in Annexin binding buffer. Cell viability was
assessed by FACS analysis following concurrent Annexin V and PI (or 7-AAD) staining.
2.2.7 Apoptosis of AML Stem/Progenitor Cells
AML mononuclear cells were isolated by Ficoll density centrifugation and cultured
with 100 nM ABT-199 or ABT-737 as described above. After 24 h, AML cells were
washed twice in Annexin binding buffer (ABB) and resuspended in 100 µL ABB
containing 1:100 dilution of Annexin-V-APC (#550475), 1:50 dilution of CD45-APC-Cy7
(#557833), CD34-FITC (#555821), CD38-PE-Cy7 (#335790) and CD123-PercP-Cy5.5
(#58714) (all from BD Biosciences) for 20 minutes at room temperature in dark.
Following staining, cells were washed with ABB and resuspended in 95 µL ABB
containing 5 µL DAPI. Cells were analyzed by Gallios Flow Cytometer (Beckman
Coulter). Results were expressed as percentage of specific apoptosis calculated by the
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formula: 100 × (% apoptosis of treated cells – % apoptosis of control cells)/(100 – %
apoptosis of control cells).
2.2.8 In vivo Study of ABT-199 Efficacy in AML Mouse Models
All animal studies were conducted in accordance with the guidelines approved by
the Institutional Animal Care and Use Committees at the University of Texas MD
Anderson Cancer Center. Twenty female NOD SCID gamma (NSG) mice (6-week-old,
Jackson Laboratory, Bar Harbor, MA) were intravenously injected with luciferaselabeled MOLM-13 cells (0.7 x 106 cells/100 μL) and randomly divided into two groups.
Four days post injection, the mice were treated with vehicle or ABT-199 (100 mg/kg
body weight) daily by oral gavage for 2 weeks. For oral dosing, ABT-199 (10 mg/mL)
was formulated in 60% phosal 50 propylene glycol, 30% polyethyleneglycol-400, and
10% ethanol. Bioluminescence imaging (BLI) was used to monitor tumor burden on
different time points. Briefly, mice were anaesthetized and injected intraperitoneally
with firefly luciferase substrate D-luciferin and then imaged noninvasively using IVIS200 in vivo imaging system (PerkinElmer, Waltham, MA). Three mice from each group
were sacrificed by CO2 asphyxiation after 15 d. Bone marrow, spleen, and liver were
collected for H&E and immunohistochemical staining. The remaining seven mice in
each group were followed for survival.
For primary AML derived xenograft models, NSG mice were sub-lethally irradiated
(250 cGy) the day prior to intravenous injection of 10 5 PDX21 patient-derived AML
cells. Three weeks following injection and after confirmation of AML engraftment, the
mice were randomly divided into two groups and treated with 100 mg/kg ABT-199 or
vehicle via gavage daily for 2 weeks. All mice were then sacrificed and femur bone
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marrows were analyzed for leukemia burden by CD45 flow cytometry (using antihuman CD45-PE antibody #555483, BD Biosciences, San Jose, CA).
2.2.9 Immunohistochemical Analysis
Immunohistochemistry was performed as described previously68. Briefly, the tissue
was formalin-fixed, paraffin-embedded, sectioned into 5 μm thickness and mounted
onto microscope slides. Tissue sections were then deparaffinized and rehydrated using
xylene and ethanol in decreasing concentration. Samples were stained with
hematoxylin

and

eosin

(H&E)

for

histopathological

evaluation.

For

immunohistochemical staining, the tissue sections were incubated with primary
antibody against human CD45 (#555480, BD Biosciences, San Jose, CA ), followed by
sequential incubation with biotinylated secondary antibody, peroxidase labeled
streptavidin and 3,3’ diaminobenzidine tetrahydrochloride/H2O2 (Dako), which resulted
in a brown precipitate at the antigen site. Images were taken using an optical
microscope under the same magnification.
2.2.10 Microarray-Based Gene Expression Profiling in AML
The expression of BCL-2 family genes was determined using oligonucleotide
microarrays (HG-U133 Plus 2.0, Affymetrix) in 288 AML samples comprising all
cytogenetic groups, and in 103 normal samples (healthy BM and non-leukemia
conditions) as described in Haferlach et al.69 All samples in this study were obtained
from untreated patients at the time of diagnosis. Cells used for microarray analysis
were collected from the purified fraction of mononuclear cells after Ficoll density
centrifugation. The study design adhered to the tenets of the Declaration of Helsinki
and was approved by the ethics committees of the participating institutions before its
initiation. The analysis is conducted at logarithm-2 transformed gene expression
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intensities. Correlation analysis based on Pearson correlation coefficient and
Spearman’s rank correlation coefficient was performed to identify probe sets that have
consistent expression pattern corresponding to a common gene. Two-sample t-test
was performed for each two-group comparison, and the P value threshold of 0.005 was
used to moderately control for multiple testing.
2.2.11 iBH3 of Primary AML Patient Cells
Thawed cells were washed 1x with PBS and stained with 1:100 Invitrogen
Live/Dead– near IR stain (#10119, Life Technologies, Grand Island, NY) in FACS
Buffer (2% FBS PBS, 1:100) for 20 min on ice, washed with FACS buffer and
subsequently stained with CD45-V450 (#642275; BD Biosciences; San Jose, CA)
1:100 FACS buffer on ice for 20 min. Cells were pelleted at 400 x g for 5 min at RT and
resuspended in DTEB. 100 μL of cells in DTEB was added to each tube containing
twice the final concentration of each peptide treatment in 100 μL of DTEB with 0.002%
w/v digitonin. Mitochondria in the permeabilized cells were exposed to peptides for 60
minutes at RT before the addition of 200 μL 4% v/v formaldehyde at RT for 15 minutes,
quenched with 50 μL of 100 mM Tris/2.5 M glycine pH 8.2 for 5 minutes at RT, and
pelleted at 1500 x g for 5 minutes at RT. Cells were stained with anti-cytochrome cAlexa488 (#560263, BD Bioscience) 1:100 in 0.1% Saponin/1%BSA/PBS overnight at
4oC and diluted 1:5 in PBS an hour before FACS on a LSR Fortessa flow cytometer
(BD Bioscience) to quantify cytochrome c loss calculated from the median fluorescence
intensity (MFI) as
% cyto c loss = 100 x (1 – ([MFIsample– MFIIsotype]÷ [MFIDMSO-MDI Isotype]))

AML blasts were identified by low-mid CD45/low SSC-A.
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2.2.12 Statistical Analysis
Statistical analyses were performed using GraphPad Prism software v6.0
(GraphPad, La Jolla, CA). Unless otherwise indicated, the results are expressed as the
mean ± standard error of the mean (SEM) from at least three independent experiments.
Differences with P values ≤ 0.05 were considered statistically significant.

2.3 Results
2.3.1 BCL-2 inhibitor ABT-199 Kills AML Cell Lines Potently and Quickly
As an initial test of the potential utility of ABT-199 in AML, we exposed AML cell
lines to increasing concentrations of ABT-199 for 48 h and then determined the IC50
values. Comparisons were made with ABT-737. As shown in Figure 2.1A, the IC50 of
ABT-199 ranged from <10 nM to >1000 nM, and sensitivity to ABT-737 roughly tracked
sensitivity to ABT-199. Prior experience with CLL, a disease for which excellent clinical
activity of ABT-199 has been observed, has revealed that CLL cells are killed in an ontarget fashion, and that the killing was evident within 4 h 70.

Therefore, we tested

whether ABT-199 could rapidly induce apoptosis in a sensitive AML cell line MOLM-13.
In Figure 1B and 1C, it can be seen that cell growth is inhibited and cell apoptosis is
observed within just a few hours of exposure to ABT-199.
To demonstrate that the efficacy seen was consistent with tolerable in vivo delivery
of ABT-199, we tested the effect of ABT-199 on an aggressive mouse xenograft model
of MOLM-13. NOD SCID gamma (NSG) mice were injected with luciferase-labeled
MOLM-13 cells and monitored by bioluminescence imaging (BLI) for tumor
development. After confirmation of AML engraftment in the bone marrow (Figure 2.1D,
day 4), the mice were treated with ABT-199 (100 mg/kg) by daily oral gavage for 2
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Figure 2.1

Figure 2.1 Selective inhibition of BCL-2 by ABT-199 kills AML cell lines quickly and
effectively.
(A) AML cell lines were treated with ABT-199 or ABT-737 for 48 h. Calcusyn software was
used to calculate the IC50 values based on the number of viable cells (i.e., Annexin V-/PI-). (B)
MOLM-13 AML cells were treated with indicated concentrations of ABT-199. Apoptosis
induction was determined by Annexin V/PI flow cytometry. (C) Viable (i.e., Annexin V-/PI-) cell
counts were quantified by FACS analysis using CountBright counting beads. (D) Serial
bioluminescence images of mice bearing MOLM-13 tumors treated with the vehicle or ABT-199
(treatment started on day 4). (E) Kaplan-Meier survival curves for mice treated as described in
E (n = 7 per arm). (F) H&E staining of histological sections of liver, spleen, and bone marrow 15
d post leukemia cell injection. Age- and sex-matched mice without tumor were used as
controls. Representative MOLM-13 cells are indicated by arrows. Representative engraftment
areas are circled in green. (G). Immunohistochemical staining of histological sections of liver,
spleen, and bone marrow with human CD45 antibody 15 d post leukemia cell injection. Scale
bar equals 50 µm.
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weeks. Serial BLI images showed that ABT-199 treatment markedly inhibited leukemia
progression, which translated into prolonged overall survival when compared to
vehicle-treated mice (P = 0.0004, Figure 2.1E). ABT-199 treated mice also carried
significantly lower leukemia burden in bone marrow, spleen and liver as indicated by
hematoxylin and eosin staining (H&E, Figure 2.1F) and immunohistochemical analysis
of human CD45 (Figure 2.1G).
2.3.2 ABT-199 Sensitivity Correlates with BCL-2 Protein Levels
Next we tested whether there were correlations between BCL-2 protein expression
levels and cell line sensitivity to ABT-199, which supported an on-target action of killing
via competition for the BH3 binding site of BCL-2. Relative levels of several BCL-2
family proteins were measured by Western blot and densitometry (Figure 2.2A).
Spearman analysis was performed to evaluate the correlation between IC50 values
and protein expression. Levels of BCL-2 correlated with sensitivity to ABT-199, while
levels of BCL-XL inversely correlated with ABT-199 sensitivity (Figure 2.2B). Levels of
MCL-1 demonstrated a trend to anti-correlation with sensitivity to ABT-199, but the
trend was not statistically significant (Figure 2.2B). These observations supported the
on-target effects of ABT-199.
The OCI-AML3 cell line was relatively resistant to ABT-199 and ABT-737 (Figure
2.1A). A quantitative immunoblot showed that OCI-AML3 cells had high expression of
BCL-2 and MCL-1 and relatively low level of BCL-XL (Figure 2.2A). If ABT-199 is a
BH3 mimetic specific for BCL-2, then MCL-1 knockdown should significantly sensitize
OCI-AML3 cells to this compound. To test this, MCL-1 protein level was reduced by
85% in OCI-AML3 cells by lentiviral transduction using a previously validated MCL1specific shRNA (Figure 2.2C). Indeed, MCL-1 knockdown greatly increased sensitivity
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Figure 2.2

Figure 2.2 Sensitivity to ABT-199 positively correlates with endogenous BCL-2 protein
level and negatively correlates with BCL-XL protein level in AML cell lines.
(A) Western blot analysis of BCL-2 family proteins in untreated AML cells. The band intensity
was quantified using Odyssey v2.0 software, and displayed numerically as a ratio of the band
intensity detected in the OCI-AML3 cells. (B) Significant correlations were observed between
ABT-199 IC50 values and BCL-2/BCL-XL protein levels. The non-parametric one-tailed
Spearman test was used to determine the correlation coefficient. The p values provided are
nominal p values not corrected for multiple comparisons. (C) MCL-1 knockdown by 85% was
achieved by lentiviral shRNA. (D) MCL-1 knockdown significantly sensitized OCI-AML3 cells to
ABT-199. (E) Western blot analysis showing HL-60 AML cells transfected to stably overexpress
BCL-XL or BCL-2. (F) Overexpression of BCL-XL or BCL-2 in HL-60 cells confers complete
resistance to ABT-199-induced apoptosis.
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to ABT-199 (Figure 2.2D). HL-60 cells with high levels of BCL-2 protein and relatively
low BCL-XL and MCL-1 expression are very sensitive to ABT-199 (Figure 2.1A). BCLXL overexpression conferred strong resistance to ABT-199 in HL-60 cells, while BCL-2
overexpression made HL-60 cells moderately resistant to ABT-199 (Figures 2.2E-F). All
these results are consistent with a killing mechanism operating via selective targeting of
BCL-2 in AML cells.
2.3.3 ABT-199 Operates Selectively on BCL-2 Dependent Mitochondria
If ABT-199 is killing cancer cells via displacement of pro-apoptotic proteins from
BCL-2, it should be operating on mitochondria. As one would expect if this were the
case, we observed a correlation between direct mitochondrial toxicity and cellular
toxicity for ABT-199 and ABT-737 in the 12 cell lines studied in Figure 2.1A (Figures
2.3A-B). We also tested whether detection of BCL-2 dependence using mitochondrial
exposure to the BAD BH3 peptide correlated with cellular sensitivity to these agents.
We found that while there was a good correlation between mitochondrial sensitivity to
the BAD peptide and drug sensitivity for the most sensitive cell lines, there was a group
of relatively drug-resistant cell lines that still demonstrated mitochondrial sensitivity to
the BAD BH3 peptide (Figures 2.3C-D). A clue to the reason for this was revealed by
the tendency of these cell lines to have mitochondria that were also quite sensitive to
the HRK peptide, an indicator of BCL-XL dependence. To ensure that we were
studying BCL-2 dependence specifically, especially in these less drug-sensitive cells,
we made a correction, by subtracting the HRK signal from the BAD signal. In Figures
2.3E-F, we used this modified metric to observe a good correlation between
mitochondrial BCL-2 dependence and cellular sensitivity.
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Figure 2.3

Figure 2.3 ABT-199 functions selectively on BCL-2 dependent mitochondria in AML cell
lines.
(A) The IC50 values of AML cell lines treated with ABT-737 from Figure 2.1A were correlated
with the mitochondrial response of ABT-737 (1µM). Mitochondrial response was measured by
JC1 based BH3 profiling. (B) IC50 values of cell lines treated with ABT-199 from Figure 2.1A
were correlated with the mitochondrial response of mitochondrial ABT-199 (0.1µM) (C). IC50
values of AML cells treated with ABT-737 were correlated with the response to the BAD BH3
(80µM). The mitochondrial responses to the BAD BH3 peptide were measured by JC1 based
BH3 profiling. (D). IC50 values of AML cell treated with ABT-199 from Figure 2.1A were
correlated with the mitochondrial response of the BAD BH3 (80uM) peptide. (E). IC50 values of
AML cells treated with ABT-737 were correlated with the response to the BAD BH3 (80µM) –
HRK BH3 (80µM). The mitochondrial responses to the BAD and HRK BH3 peptides were
measured by JC1 based BH3 profiling. (F). IC50 values of AML cells treated with ABT-199 from
Figure 2.1A were correlated with the mitochondrial response of the BAD BH3 (80uM) – HRK
BH3 (80uM) peptide. Statistical correlation was performed using a one-tailed Spearman r using
GraphPad Prism 6.
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2.3.4 ABT-199 Efficiently Kills Primary AML Myeloblasts
We observed ABT-199 selectively kills BCL-2 dependent cell lines. Therefore, we
next wanted to test the sensitivity of primary patient AML samples to ABT-199. Clinical
and genetic data for both sets of AML samples is available in Table 2.1. AML
myeloblasts from patient bone marrow or peripheral blood were exposed to ABT-199
for 48 h in minimum essential medium alpha supplemented with cytokines. It is notable
that the primary cells were quite sensitive, with median IC50 values less than 10 nM
(Figure 2.4A). Note that this is significantly lower than the IC50 observed in the AML
cell lines (Figure 2.1A). Note also that this is comparable to the sensitivity observed for
ex vivo exposure of CLL cells, a disease in which ABT-199 has shown clinical activity in
most patients treated.
Because prolonged ex vivo culture by itself can promote sensitivity to apoptosis of
AML myeloblasts, we wanted to test whether we would see sensitivity at shorter time
points as well. Therefore, we tested sensitivity of AML myeloblasts to ABT-199 at 8 h
(Figure 2.4B). Again, AML myeloblasts proved to be sensitive to ABT-199 with a
median IC50 of 20 nm. Indeed, when we reduced exposure times further, to 2 hours,
we could still see induction of apoptosis by ABT-199 in AML myeloblasts (Figure 2.4C).
Similarly rapid induction of cell death has been observed for the clinically sensitive CLL,
consistent with a direct action of ABT-199 on AML myeloblast mitochondria, promoting
apoptosis in the absence of a requirement for additional cell signaling extrinsic to the
mitochondria.
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Table 2.1 Clinical characteristics of AML patients

Abbreviations: BM, bone marrow; PB, peripheral blood; “+”, Positive; “−”, None detected; U, unknown.
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Figure 2.4

Figure 2.4 ABT-199 efficiently kills primary AML myeloblasts as a single agent.
(A) IC50 determination for ABT-199 and ABT-737 treatment of primary AML samples. Fresh
mononuclear cells from AML patients were isolated from bone marrow or peripheral blood and
treated for 48 h. The IC50 values were calculated based on viable (i.e., Annexin V-/PI-) cell
numbers determined by FACS analysis. Samples with ABT-199 IC50 < 0.1 μM were defined
as “sensitive”, while those with ABT-199 IC50 > 1 μM were defined as “resistant”. (B) Frozen
primary AML myeloblasts were thawed treated with ABT-199 and ABT-263 for 8 h in the
absence of fetal bovine serum. Viability was assessed by Annexin-/PI- via FACS analysis and
Figure 2.4 Legend (continued)
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IC50 values were calculated using GraphPad Prism software. (C) Thawed primary AML
samples were treated for 2 h with 1-1000 nm of ABT-199 and viability was assessed by
Annexin V-PI- by FACS analysis (D) Nonparametric Spearman correlation analysis shows a
significant (p
= 0.017) negative correlation between ABT-199 IC50 values and BCL-2 protein levels. (E) A
non-significant (p = 0.069) positive correlation was observed between ABT-199 IC50 values
and BCL-XL protein levels. (F) Boxplots represent the quartiles and range of log2 values of
mRNA expression for BCL-2 genes in different subgroups of AML and normal bone marrows.
The median is indicated by the black line in each box. Numbers on top indicate number of
patients in each specified subgroup. Differences in gene expression with P values ≤ 0.005 were
considered statistically significant, as denoted by *. (G) Patient AML samples treated with 100
nM ABT-199 for 24 hours were subjected to FACS analysis of specific apoptosis based on
Annexin V staining in the bulk AML myleoblast and CD34+/CD38-/CD123+ LSC-containing
population.
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Upon testing of additional cryopreserved AML patient samples, including AML cells
with diploid cytogenetics and mutations in FLT3, NRAS, and NPM1 genes, 20 out of 25
(80%) were sensitive to ABT-199 (100 nM). However, samples from patients with
complex cytogenetics and JAK2 mutation (n = 9) were largely insensitive to ABT-199 (1
of the 9, or 11.1% response rate, P = 0.0005 by two-tailed Fisher exact test). Further
we found no correlation between ABT-199 sensitivity and FAB classification or NPM1
or FLT3 mutational status. There was no difference in ABT-199 sensitivity between
samples sensitive or resistant to conventional induction chemotherapy (Figure 2.5),
consistent with prior findings with ABT-73762. We next tested whether sensitivity to
ABT-199 correlated with protein expression for primary AML myeloblasts. As we found
with AML cell lines, sensitivity to ABT-199 correlated directly with BCL-2 expression
and inversely with BCL-XL expression as measured by quantitative Western blot
(Figure 2.4D-E). AML myeloblasts also demonstrate higher BCL-2 mRNA expression
than normal bone marrow samples (Figure 2.4F).
2.3.5 ABT-199 Induces Apoptosis in AML Stem/Progenitor Cells (LSPCs)
We next tested whether ABT-199 is capable of inducing cell death not only in AML
blasts, but also in the phenotypically defined AML stem/progenitor cells characterized
by CD34+CD38-CD123+ immunophenotype71. Samples from six ABT-199-sensitive
AML patients with high blast counts were incubated with ABT-199 for 24 h, and
apoptosis induction was determined by Annexin V flow cytometry in electronically gated
AML

blasts

(CD45dimSSClow)

and

AML

stem/progenitor

cells

(CD45dimSSClowCD34+CD38-CD123+). ABT-199 induced apoptotic cell death in both
bulk AML blasts and AML stem/progenitor cells (Figure 2.4G). It appeared that AML
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Figure 2.5

Figure 2.5 Clinical characteristics of AML patients do not correlate with ABT-199
sensitivity.
(A) Patients from Figure 4B were classified by their FAB status ( French-American-British
classification). There was no significant difference between the IC50 values between various
cohorts (note, M1 was not included in the analysis because there were not enough samples to
perform the analysis). (B) Patient samples used in Figure 4B were stratified by their
nucleophosmin 1 status (an NPM1 mutation is a good prognostic factor). There was no
difference in IC50 values between patients who had an NPM1 mutation and those who were
WT. (C) Patient samples used in Figure 4B were stratified by their FLT3 status (an FLT3
mutation is a poor prognostic factor). There was no difference in IC50 values between patients
who had an FLT3 mutation and those who were WT. (D) Patient samples used in Figure 4B
were stratified into newly diagnosed patients who achieved a complete response (CR), newly
diagnosed patients who did not achieve a CR and relapsed patients. There is no difference in
ABT-199 IC50 values between the three groups. A Mann-Whitney t test was used for these
comparisons.
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stem/progenitor cells are more sensitive to ABT-199 (P = 0.009), consistent with
previous report that leukemia stem cells overexpress BCL-2 and are dependent on
BCL-2 for energy homeostasis and survival72.
2.3.6 BH3 Profiling Predicts AML Myeloblast Killing by ABT-199
We next tested whether killing of primary AML myeloblasts by ABT-199 acted as a
true BH3 mimetic in an on-target fashion on BCL-2 dependent mitochondria. If this
were the case, we would expect that mitochondria sensitive to the BAD BH3 peptide
should also be sensitive to the ABT-199. Indeed, we found an extremely tight
correlation between mitochondrial sensitivity to BAD BH3 and ABT-199 across 30
independent patient samples (Figure 2.6A). No such correlation was observed for the
comparison of the BCL-XL selective peptide HRK BH3 and the IC50 of ABT-199,
supporting BCL-2 selective action of ABT-199 (Figure 2.6B). We observed a weak anticorrelation between cellular sensitivity to ABT-199 and sensitivity to the MCL-1
selective peptide NOXA BH3 (Figure 2.6C). This suggests that there is a minor
tendency for MCL-1 dependent mitochondria to be less sensitive to ABT-199.
In other diseases, BH3 profiling has proven a useful tool for predicting the cytotoxic
effect of BH3 mimetic small molecules73,74. Here we tested whether BH3 profiling using
the BAD BH3 peptide predicted cytotoxicity from ABT-199, and found that the
correlation was very good (Figure 2.6D). In addition, the mitochondrial effect of ABT199 correlated well with the cytotoxic effect (Figure 2.6E), again supporting a direct
mitochondrial effect of ABT-199, consistent with a mechanism of action of direct
competition for the BH3 binding site of BCL-2 on mitochondria.
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Figure 2.6

Figure 2.6 BH3 profiling predicts AML myeloblast killing by ABT-199
(A) Intracellular BH3 (iBH3) profiling was performed on thawed primary AML cells using the
BAD BH3 (80 µM) and ABT-199 (1µM). The mitochondrial sensitivity to BAD BH3 and ABT-199
were positively correlated. (B) There is no correlation between the IC50 of primary AML
samples from Figure 2.4B with the BCL-XL specific BH3 peptide HRK (80 µM). (C) The IC50 of
primary AML samples from Figure 2.4B were correlated with the NOXA (80µM), a MCL-1
specific NOXA BH3 peptide. (D) The ABT-199 IC50 of primary AML samples from Figure 2.4B
were correlated with the BAD BH3 peptide (80uM). (E) The ABT-199 IC50 from Figure 2.4B
was correlated with the ABT-199 mitochondrial response (1µM). All correlations were tested
using a one-tailed Spearman r correlation using GraphPad Prism software.
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2.3.7 BH3 Profiling Predicts Response to ABT-199 in AML Xenograft Models
Tumor xenograft models established by inoculation of cancer cell lines into
immunodeficient mice have been used widely for testing novel therapies. However,
cultured tumor cells can undergo changes in their gene expression patterns after
prolonged passage in vitro. Therefore, the preclinical results obtained from patienttumor derived xenograft (PDX) models may offer superior modeling of the human
disease, especially for testing target-oriented therapies. We have shown that ABT-199
was very effective in a murine AML cell line xenograft model (Figure 2.1E). As a more
clinically relevant test of ABT-199’s anti-leukemic efficacy in vivo, NSG mice were
injected with primary AML cells from two different patients (R and S) and monitored for
leukemia engraftment by measurements of human CD45+ cells in peripheral blood.
After confirmation of AML engraftment, the mice were randomly divided into vehicle
and treatment groups. Treated mice received ABT-199 for 2 weeks, after which all the
mice were sacrificed, and bone marrows were examined for AML tumor burden by
human CD45 flow cytometry. FACS analysis showed that ABT-199 treatment
significantly reduced leukemia burden in murine bone marrows in mice injected with
cells from patient S (mean, 70 ± 16% human CD45+ cells in bone marrow of control
mice and 32.7 ± 12% in ABT-199 treated mice, P = 0.0004, Figure 2.7A). We did not
observe a decrease in tumor burden in mice injected with cells from patient R (mean
70.3 ± 8.1% human CD45+ cells in bone marrow of control mice and 74.3 ± 6.4% in
ABT-199 treated mice, P = 0.1930, Figure 2.7B).
Since we observed a difference in response in the xenograft model following ABT199 treatment, we asked whether the response to ABT-199 could be predicted by BH3
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Figure 2.7

Figure 2.7 BH3 profiling predicts AML progression in a primary AML xenograft model
(A-B) NSG mice were injected with primary AML cells as described under Methods. Mice were
treated with ABT-199 100 mg/kg oral daily dose starting 3 weeks after AML cell injection, for
two weeks. The graph represents % of human CD45+ leukemic cells in the murine bone
marrow in mice sacrificed upon completion of the therapy. A non-parametric, unpaired, twotailed t-test was used to evaluate the significance of mean difference. (C) Intracellular BH3
profiling using the BAD BH3 (80 μM) and ABT-199 (10 μM) was performed on pre-treatment
patient samples.
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profiling. In a blinded fashion, pre-treatment AML myeloblasts from each model were
subjected to BH3 profiling in which mitochondria were exposed to the BAD BH3 peptide
as well as ABT-199 itself. We found that mitochondria from AML myeloblasts from
patient S released more cytochrome c following incubation with the BAD peptide or
ABT-199 compared to patient R (Figure 2.7C). These results provide evidence that
ABT-199 kills AML myeloblasts by the expected mechanism of inhibition of
mitochondrial BCL-2. Furthermore, these results suggest that BH3 profiling might
predict the response of AML primary cells to ABT-199 in vivo.
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__________________________________
Chapter 3 p53 Activation and BCL-2 Inhibition Reciprocally
Overcome Apoptosis Resistance to Either Strategy Alone:
The Novel Mechanisms and Superior Antileukemic Efficacy

__________________________________
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3.1 Chapter Introduction
Evasion of apoptosis is integral to tumorigenesis and drug resistance 7,17.
Upregulation of anti-apoptotic BCL-2 family members and inactivation of p53 functions
are two canonical approaches exploited by cancer cells to escape apoptosis 5,7,8,17. Both
approaches shift the balance of anti- and pro-apoptotic proteins toward survival and
render cancer cells resistant to various therapies. Tremendous efforts to develop BCL2 inhibitors culminated in ABT-199 (abbreviated here as ABT), a selective and potent
BCL-2 inhibitor that showed promising efficacy in several cancers4,5,27. The advent of
ABT allows scientists to specifically study BCL-2 inhibition in cancers.
TP53, arguably the most important tumor suppressor gene, is mutated in ~50% of
human solid tumors but rarely in hematological malignancies75,76. However, wild-type
p53 functions are frequently suppressed by MDM2, an E3 ubiquitin ligase that targets
p53 for proteasomal degradation77,78. Nutlins, the first-generation MDM2 inhibitors,
represented a breakthrough in the development of p53-reactivating compounds47. The
recently developed RG7388 (RG) is a second-generation MDM2 inhibitor with greater
potency, selectivity, and bioavailability compared to its predecessors Nutlin-3a and
RG711248. In the current study, we first demonstrated that RG could robustly activate
p53 and that RG-induced apoptosis was highly dependent on p53, indicating that RG
can serve as an ideal compound to study p53 activation.
We have reported previously that targeting BCL-2 by ABT effectively induced
apoptosis in AML cells. However expression of MCL-1, another critical anti-apoptotic
protein, renders leukemia cells resistant to BCL-2 selective ABT or its predecessor
ABT-73711,29,79. In the current study, we initially hypothesized that p53 activation by RG
could overcome resistance to BCL-2 inhibition by inducing pro-apoptotic proteins such
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as Puma and Noxa to counteract MCL-1. To our surprise, p53 activation also
negatively regulated N-Ras protein to downregulate the Ras/Raf/MEK/ERK pathway.
This, in turn, activated GSK3 protein to promote MCL-1 phosphorylation and
degradation, thus overcoming MCL-1–mediated resistance. Moreover, we found that
leukemia cells that are resistant to BCL-2 inhibition can also be resistant to p53
activation. In fact, p53 activation induced high levels of p21WAF1/Cip1, which then
mediated reversible G1 arrest and protected cancer cells from apoptosis induction by
p53. We developed a novel method to simultaneously analyze apoptosis and cell cycle
distribution of viable cells and unambiguously illustrated that BCL-2 inhibition can
switch the outcomes of p53 activation from pro-survival G1 arrest to apoptotic cell
death, thus overcoming the apoptosis resistance to p53 activation. We demonstrated,
both mechanistically and therapeutically, that BCL-2 inhibition and p53 activation could
reciprocally overcome apoptosis resistance to either strategy alone in vitro and in three
resistant mouse models of leukemia.

3.2 Materials and Methods
3.2.1 Cell Lines and Tissue Culture
Acute myeloid leukemia (AML) and other cell lines were purchased from the
American Type Culture Collection (Manassas, VA, USA) or Deutsche Sammlung von
Mikroorganismen und Zellkulturen (Braunschweig, Germany) and maintained according
to the vendors’ instructions. OCI-AML3, MOLM-13, MV-4-11, KG1, HL-60 and THP1
were validated by short tandem repeat DNA fingerprinting using the Amp-FlSTR
Identifier kit according to the manufacturer’s instructions (Thermo Fisher Scientific,
Waltham, MA). Cells were cultured at 37°C in a humidified atmosphere containing 5%
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CO2. Exponentially growing parental and generated cells were used for all in vitro and
in vivo studies.
3.2.2 Generation of AML Cells with Acquired Resistance to ABT
Parental MOLM-13 and MV-4-11 cells were cultured in RPMI-1640 medium (10%
fetal bovine serum [FBS]) supplemented with escalating doses of ABT (starting at IC50
doses for each cell line). Every 2 days, the cells were pelleted by centrifugation (1000g,
5 min) and resuspended in fresh medium with ABT. Cell viability was monitored by ViCELL viability analyzer (Beckman Coulter). Once the viability reached ≥ 90%, the
concentration of ABT was increased by one fold. The generated cells were at least 30
times more resistant than their parental cells (Figure 2.2A).
3.2.3 Concurrent Apoptosis and Cell Cycle Analysis
Exponentially growing cells were treated with vehicle, ABT, RG or ABT-RG
combination for the indicated time. Then Edu (10 mM in phosphate-buffered saline
solution [PBS]) was added to a final concentration of 10 μM. After incubation under
optimal growth conditions for 1 h, cells were washed with 3 mL ice-cold ABB buffer and
pelleted by centrifugation at 4°C (1000g, 5 min). Supernatant was carefully removed by
aspiration without disturbing the cell pellet. The cells were then placed on ice, mixed
with 50 μL ABB containing 5 μL AnnV-Alexa488 (Life Technologies) and incubated in
darkness for 15 min. After staining, cells were washed again with ice-cold ABB. The
cells were fixed, permeabilized and then incubated with Click-iT Plus reaction cocktail
(Life Technologies) according to the manufacturer’s instructions. After the Click-iT
reaction, cells were mixed well with 0.5 mL of FxCycle PI/RNase solution (Life
Technologies) by gentle vortexing. Following 30 min of incubation in darkness at 37°C,
CountBright™ Counting Beads were added and the samples were analyzed by flow
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cytometry for apoptosis (AnnV+) and cell cycle distribution of AnnV- live cells (Figure
2.5G for gating strategy).
3.2.4 Immunoblotting and Antibodies
Cells were subjected to lysis at a density of 1 x 10 6/50 μL in protein lysis buffer
(0.25 M Tris-HCl, 2% sodium dodecylsulfate, 4% β-mercaptoethanol, 10% glycerol,
0.02% bromophenol blue) supplemented with 1x protease/phosphatase inhibitor
cocktail (#5872, Cell Signaling Technology, Beverly, MA, USA). Cell lysates were then
loaded onto polyacrylamide gels with sodium dodecyl sulfate (Bio-Rad, Hercules, CA,
USA). After electrophoresis, proteins were transferred to polyvinylidene difluoride
membranes. The transblotted membranes were blocked for 1 h and then probed with
appropriate primary antibodies (dilution as recommended by manufacturers) overnight
at 4°C. Next, the membranes were washed three times for a total of 30 min and then
incubated with secondary antibodies in darkness at room temperature for 1 h. After
another three washes, Odyssey infrared imaging system and companion software (LICOR Biosciences, Lincoln, NE, USA) were used to scan immunoblot membranes and
to quantify band intensity according to the manufacturer’s manual. The ratios of
proteins of interest/loading control in treated samples were normalized to their
counterparts in untreated cells. Antibodies for immunoblotting were purchased from the
following sources: p53 (sc-126), MDM2 (sc-5304), BCL-2 (sc-7382), MCL-1 (sc-819),
Puma (sc-28226), ERK (sc-1647), N-Ras (sc-31) and GSK3 (sc-7291) from Santa Cruz
Biotechnology (Dallas, TX, USA); pERK (T202/Y204, 4370), pMEK (S217/S221, 9121),
MEK (4694), AKT (2920), pAKT(S473, 9271), pGSK3 (S21/S9, 8566), PARP-1 (9542),
Bim (2819), Bak (12105),caspase-3 (9664), caspase-9 (9508), pMCL-1 (T163, 14765),
B-Raf (9433), pB-Raf (S445, 2696), JNK (9252) and pJNK (T183Y185, 9255) from Cell
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Signaling Technology; Bax (B8554) and β-Actin (A2228) from Sigma-Aldrich; NOXA
(ab13654) and pMCL-1 (T163S159, ab111574) from Abcam; p21 (OP64) from EMD
Millipore (Darmstadt, Germany). IRDye 680 donkey anti-rabbit and IRDye 800 donkey
anti-mouse secondary antibodies were purchased from Li-COR Biosciences.
3.2.5 Stable Overexpression of MCL-1
MCL-1 expression cassette was delivered into MV-4-11 and MOLM-13 cells by
lentiviral transduction. Briefly, the open reading frame of human MCL1 cDNA
(IMAGE:3826638) was inserted between the NheI and BamHI sites of a commercially
available lentiviral transfer vector pCDH-EF1-MCS-BGH-PGK-GFP-T2A-Puro (System
Biosciences, Mountain View, CA, USA). After verification of the construction by Sanger
sequencing, lentivirus was prepared and used to transfect AML cells as described
above. In parallel, control cells were transduced with lentivirus delivering GFP coding
sequence. Infected cells were selected with puromycin starting at 0.5 μg/mL. Increased
expression of MCL-1 was verified by immunoblot analysis.
3.2.6 Isolation and Treatment of Primary AML Cells
Primary samples from AML patients at The University of Texas MD Anderson
Cancer Center were obtained with informed consent according to protocols approved
by the Institutional Review Board. Mononuclear cells were isolated from peripheral
blood or bone marrow samples by Ficoll density centrifugation. The primary cells were
used immediately or resuspended in 90% FBS plus10% DMSO and viably
cryopreserved in liquid nitrogen for future use. The isolated cells were treated with
different compounds or combinations in RPMI-1640 medium supplemented with 10%
FBS (final concentration of DMSO vehicle < 0.1%). After 48 h, cell viability was
determined by flow cytometry following concurrent AnnV and PI staining. Samples with
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a spontaneous apoptosis rate > 30% were excluded from our analysis.
3.2.7 Animal Studies
All animal studies were performed in accordance with protocols approved by MD
Anderson Cancer Center Institutional Animal Care and Use Committees. NOD SCID
gamma (NSG) mice (6 wk old; Jackson Laboratory, Bar Harbor, ME, USA) were
intravenously injected with AML cell lines or primary patient cells as indicated in
schematic outlines for each mouse model (Figures 3.2D, 3.3G, and 3.6C). After
confirmation of engraftment, the mice were randomly assigned to four groups (n = 10
per group) and treated with vehicle, ABT (100 mg/kg), RG (100 mg/kg) or the
combination daily by oral gavage. ABT was prepared weekly in 10% ethanol, 30%
polyethyleneglycol-400, and 60% phosal 50 propylene glycol (provided by AbbVie). RG
was formulated daily in 4% DMA, 30% PEG400 and 66% Gelucire 44-14 (provided by
Roche). Leukemic burden of luciferase-labeled OCI-AML3 or MOLM-13-R cells was
monitored by bioluminescence imaging at multiple time points. Briefly, mice were
anesthetized and injected intraperitoneally with firefly luciferase substrate D-luciferin
(Gold Biotechnology, St. Louis, MO, USA) and then imaged by IVIS-200 in vivo imaging
system (PerkinElmer, Waltham, MA, USA). After treatment for the indicated time, three
mice were randomly selected from each group and euthanized by CO 2 asphyxiation.
Left femur, spleen, and liver were harvested for IHC staining with human CD45
antibody. For the PDX mouse model of resistance, BM cells from the right femur were
also collected and stained with human CD45-PE and murine CD45-APC antibodies
(BD Biosciences) followed by flow cytometry analysis. The remaining seven mice in
each group were monitored for survival.
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3.2.8 Gene Knockdown by shRNA
p53, MCL-1 and p21 encoding genes (TP53, MCL1, and CDKN1A) were knocked
down by lentivirus delivering well-validated shRNAs in pLKO.1 vector (Addgene,
Cambridge, MA, USA). In parallel, control cells were transduced with lentivirus
delivering a hairpin targeting GFP. Briefly, lentivirus was prepared by co-transfection of
log-phase HEK293T cells with an equimolar mix of transfer vector psPAX2 and
packaging plasmid pMD2.G (Addgene) using JetPrime transfection reagent according
to the manufacturer’s instructions (Polyplus, Illkirch, France). Lentiviral supernatants
were harvested 48 h after transfection by centrifugation (800g, 10 min) at room
temperature. The supernatant was then filtered through 0.45 μM surfactant-free
cellulose acetate membranes to remove lentivirus-producing cells. Polybrene
(Chemicon, Temecula, CA, USA) was added to a final concentration of 8 μg/mL, and
the virus stock was used immediately to transfect AML cell lines.

Exponentially

growing cells were resuspended at a concentration of 0.5 × 10 6 cells per mL of virus
stock, transferred to 12-well tissue plates, and centrifuged for 45 min (1300 g, 30°C).
After adding one volume of fresh virus stock, the cells were centrifuged again and
incubated in a tissue culture incubator (37°C, 5% CO2) for 1 h. The cells were then
washed twice with growth medium to remove the polybrene and returned to the tissue
culture incubator. After two doubling times (42–44 h), infected cells were subjected to
selection with 0.5 μg/mL puromycin (Invitrogen, San Diego, CA, USA). Generated
knockdown cells were assessed by immunoblot using MCL-1, p53 and p21 antibodies.
Because of the low basal expression of p53 and p21 in OCI-AML3, MOLM-13 and MV4-11 cells, the control and knockdown cells were treated with 1 μM RG for 12 h prior to
immunoblot analysis.
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3.2.9 Immunohistochemical (IHC) Analysis
IHC analysis of human CD45 was performed as described in Methods section of
Chapter 2. The monoclonal mouse anti-human CD45 antibody (M0701) was purchased
from DAKO (Carpinteria, CA, USA). Images were acquired by an OLYMPUS BX43
microscope with DP72 digital color camera and companion software CellSens
(Olympus, Upper Saucon Township, PA, USA).
3.2.10 Measurement of Apoptosis, Live Cell Number and IC50 Values
As described in the Method section of Chapter 2.
3.2.11 Statistical Analysis
Statistical analyses were performed using Prism software v6.0 (GraphPad
Software, La Jolla, CA, USA). The log-rank test was used to compare mouse survival
curves. For in vitro studies, statistical significance was determined by the two-tailed
unpaired Student’s t-test. A P value < 0.05 was considered statistically significant. NS,
not significant, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Unless otherwise
indicated, data represent the mean ± standard deviation from at least three
independent experiments.

3.3 Results
3.3.1 RG Activates p53 and Induces Apoptosis in a p53-Dependent Manner
We first tested whether the MDM2 inhibitor RG depends on wild type p53 for its
activity using Annexin V (AnnV) and propidium iodide (PI) co-staining followed by flow
cytometry analysis (Figure 3.1A). In three p53 wild-type (p53wt) AML cell lines (MV-411, OCI-AML3, and MOLM-13), RG induced a rapid accumulation of p53 as well as a
time- and dose-dependent apoptosis induction and growth inhibition (Figures 3.1B-C,
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S3.1A-B). In contrast, RG did not trigger apoptosis in p53 null HL-60 or p53mutant KG1
and THP1 cells (Figure 3.1D). Furthermore, stable p53 knockdown substantially
attenuated RG efficacy in three p53wt cell lines (Figures 3.1E-F). These results
demonstrate that RG can effectively activate p53 and induce apoptosis in a p53dependent manner, indicating that RG can be used as a superior tool compound to
study p53 activation.
MV-4-11 and MOLM-13 are sensitive to the BCL-2–specific inhibitor ABT (IC50
values < 20 nM). Combining p53 activator RG with ABT at a 5:1 or 1:1 ratio augmented
apoptosis and reduced live cell numbers to a significantly greater extent than either
agent alone (Figures S3.1C-D). RG decreased ABT’s IC50 values from 11.6 to 2.2 nM
for MV-4-11 and from 15.2 to 3.6 nM for MOLM-13. The combination index (CI) values
also indicated a strong synergy between BCL-2 inhibitor ABT and p53 activator RG in
ABT-sensitive cells (Figure S3.1E).
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Figure 3.1

Figure 3.1 MDM2 inhibitor RG activates p53 and induces apoptosis in a p53-dependent
manner.
(A) Flow cytometry plots showing gating strategy to determine apoptosis (AnnV+) and the
numbers of live cells (AnnV−/PI−). (B) Time- and dose-dependent induction of apoptosis and
reduction of live cell numbers by RG in MV-4-11 cells. (C) Immunoblot of MV-4-11 cells treated
with RG for 8 h. β-actin served as loading control. (D) RG induced apoptosis and reduction of
live cell numbers in p53wt cells but not in p53null HL-60 or p53mutant KG1 and THP1 cells. (E)
Immunoblot showing stable p53 knockdown by lentiviral shRNA in three AML cell lines
(Because of low basal expression of p53, cells were treated with 1 μM RG for 12 h to increase
p53 levels prior to immunoblot). (F) p53 knockdown reduced apoptosis induction and cell killing
by RG.
AML cells were treated with indicated concentration of RG for 48 h (D, F). The cell numbers
were enumerated by flow analysis using CountBright counting beads and normalized to
untreated controls (B, D, F). All data in bar graphs represent the means of triplicate
experiments. Error bars, mean ± SD.
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Figure S3.1

Figure S3.1 related to Figure 3.1.
(A) Time- and dose-dependent induction of apoptosis and reduction of live cell numbers by RG
in OCI-AML3 and MOLM-13 cells. (B) Immunoblot of MV-4-11 and OCI-AML3 cells treated with
RG for 8 or 16 h. β-actin served as loading control. (C-E) RG synergized with ABT at a 5:1(C)
or 1:1 ratio (D) in ABT-sensitive MV-4-11 and MOLM-13 cells. The combination index (CI) and
IC50 values were calculated with Calcusyn software based on live cell numbers (E).
AML cells were treated with indicated concentration of RG for 48 h (A, C, D). Data in bar/line
graphs represent the means of triplicate experiments (A, C, D). Error bars, mean ± SD. *** P <
0.001 as determined by two-tailed unpaired Student’s t-test.
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3.3.2 p53 Activation Overcomes Acquired Resistance to BCL-2 Inhibition
Although initially sensitive to BCL-2 inhibitor ABT, MOLM-13 and MV-4-11 cells
acquired resistance after prolonged exposure to ABT. While BCL-2 inhibition readily
induced apoptosis in parental cells, only marginal apoptosis occurred in resistant cells
(MOLM-13-R and MV-4-11-R, Figure 3.2A). The ABT IC50 increased by over 30- and
80-fold for MOLM-13-R and MV-4-11-R, respectively. Compared to their parental
counterparts, the resistant cells expressed similar levels of BCL-2, but higher levels of
MCL-1 (Figure 3.2B). Ectopic MCL-1 expression also conferred resistance to ABT in
initially sensitive MOLM-13 and MV-4-11 cells (Figures S3.2A-D), indicating that the
acquired resistance could be attributed, at least in part, to the elevated expression of
MCL-1.
Next we examined if the acquired resistance to BCL-2 inhibition could be abrogated
by p53 activation. BCL-2 inhibition by ABT triggered little apoptosis in the resistant
MOLM-13-R/MV-4-11-R cells. However, the combination of p53 activator RG with ABT
markedly induced apoptosis and decreased live cell numbers (Figures 3.2C and 3.2E),
implying that the acquired resistance could be abrogated by p53 activation (Similarly,
RG overcame ABT resistance in MOLM-13/MV-4-11 cells with ectopic MCL-1
expression; Figures S3.2E-F). To test this in vivo, we labeled the resistant MOLM-13-R
cells with luciferase (Luci) and injected them into NOD SCID gamma (NSG) mice
(Figure 3.2D). After confirmation of engraftment by bioluminescence imaging (BLI), the
mice were randomly assigned to four groups (n = 10/group) and treated with vehicle,
ABT, RG, or the combination. After 2-wk treatment, the leukemic burden in the
combination group was ~1/200 of that in the ABT/control groups and ~1/19 of that in
the RG group (Figures 3.2F and 3.2H). Meanwhile, the combination dramatically
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reduced leukemic infiltration in spleen, liver, and bone marrow (BM, Figure 3.2G).
MOLM-13-R cells rapidly killed control and ABT-treated mice at about the same time
(Figure 3.2I). p53 activator RG prolonged survival by 6 d, while the combination
significantly extended mouse survival by 20 d (a 3.3-fold prolongation relative to RG
monotherapy, Figure 3.2I). These results indicate that p53 activation by RG could
overcome acquired resistance to BCL-2 inhibition in vivo.
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Figure 3.2

Figure 3.2 Sensitive AML cell lines acquire resistance to BCL-2 inhibitor ABT; p53
activator RG overcomes the acquired resistance in vitro and in vivo.
(A) Sensitivity comparison of parental (P) and generated resistant (R) cells after treatment with
ABT for 48 h. The IC50 values were calculated with Calcusyn software based on live cell
numbers. (B) Immunoblot showing MCL-1 upregulation in cells with acquired resistance. (C
and E) The resistant cells were treated with ABT, RG or ABT-RG combination at a 1:1 ratio for
48 h. (D) Schematic outline of the mouse model of acquired ABT resistance (MOLM-13-R).
Treatment was started after confirmation of AML engraftment on day 0 (4 days post-injection).
(F) Serial bioluminescence images of mice bearing MOLM-13-R cells treated with vehicle, ABT,
RG or the combination. (G) Representative immunohistochemical (IHC) staining of murine
bone marrow, spleen and liver for human CD45 antigen on day 14. Three mice from each
group were sacrificed. Rare leukemic cells in tissue sections from combination-treated mice
were marked by green arrows. (H) Quantification of bioluminescence emitted from the whole
body of each mouse. Data represent the mean ± s.d. of each group. (I) Kaplan-Meier survival
curves of mice injected with MOLM-13-R cells (n = 7 per group; statistical significance was
evaluated by the log-rank test).
Data in bar/line graphs (A, C, E) represent the means of triplicate experiments. Error bars,
mean ± SD.
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Figure S3.2

Figure S3.2 related to Figure 3.2. MCL-1 overexpression confers resistance to BCL-2
inhibitor ABT, which can be abrogated by p53 activator RG.
(A, B) Immunoblot showing stable MCL-1 overexpression in MOLM-13 and MV-4-11 cells.
GFP, control transfectants. β-actin served as loading control. (C, D) MCL-1 overexpression
rendered MOLM-13 and MV-4-11 cells resistant to ABT. Cells were treated with ABT for 48 h.
(E, F) RG could overcome MCL-1–mediated resistance to ABT. Control and MCL-1–
overexpressing MOLM-13/MV-4-11 cells were treated with RG and ABT at a 1:1 ratio for 48 h.
Data in bar/line graphs represent the means of triplicate experiments. Error bars, mean ± SD
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3.3.3 p53 Activation Abrogates Inherent Resistance to BCL-2 Inhibition
OCI-AML3 cells express a high level of MCL-1 and are inherently resistant to BCL2 inhibitor ABT (Figures 3.3A-B). Both MCL-1 knockdown

11

and a selective MCL-1

inhibitor A-1210477 abolished ABT resistance (Figure S3.3), further validating MCL-1
as an inherent resistance factor in OCI-AML3 cells. We then asked whether the
inherent resistance could be abrogated by RG-mediated p53 activation. Combining RG
with ABT at a 3:1 or 1:1 ratio increased apoptosis and decreased live cell numbers to a
significantly greater extent than either agent alone (Figures 3.3C-D). p53 activator RG
reduced ABT IC50 from 1590 to 26 nM. These results indicate that p53 activation could
overcome the inherent resistance to BCL-2 inhibitor ABT. Importantly, RG failed to
overcome the inherent resistance in p53 knockdown cells (Figure 3.3E), implying the
pivotal role of p53 activation in this process.
To determine if p53 activation could overcome the inherent resistance in vivo, we
labeled OCI-AML3 cells with luciferase and injected them into NSG mice (Figures 3.3FG). Seven days post-injection, engraftment was confirmed by BLI (Figure 3.3H). The
mice were then randomly divided into four groups and treated with vehicle, ABT, RG, or
the combination. BCL-2 inhibition by ABT slightly reduced leukemic burden as indicated
by BLI and immunohistochemical (IHC) analysis (Figures 3.3H-J). p53 activator RG
significantly decreased tumor burden, while the combination further slowed leukemia
progression and reduced tumor infiltration in BM, spleen, and liver to a greater extent
than either agent alone (Figures 3.3H-J). The ABT-RG combination markedly extended
mouse survival by 61 d (3.2- and 6.1-fold prolongation relative to RG or ABT
monotherapy, respectively; Figure 3.3K). These data suggest that p53 activation can
overcome the MCL-1–mediated inherent resistance to BCL-2 inhibition in vivo.
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Figure 3.3

Figure 3.3 p53 activation by RG abrogates inherent resistance to ABT.
(A) Basal expression of MCL-1 and BCL-2 in MOLM-13, MV-4-11 and OCI-AML3 cells. (B)
MCL-1high OCI-AML3 cells are inherently resistant to ABT. AML cells were treated with ABT for
48 h. Effects = 1 – live cell numbertreated/live cell numbercontrol. (C and D) RG synergized with
ABT at a 3:1 ratio (C) or a 1:1 ratio (D). The combination index (CI) and IC50 values were
calculated using Calcusyn software based on live cell numbers. (E) RG overcame ABT
resistance in control but not in p53 knockdown OCI-AML3 cells (48 h treatment). (F) RG
abrogated ABT resistance in luciferase-labeled OCI-AML3 cells in vitro (48 h treatment). (G)
Schematic outline of the mouse model of inherent ABT resistance. (H) Serial bioluminescence
images of OCI-AML3–engrafted NSG mice. Treatment was initiated on day 7 after confirmation
of engraftment. (I) Representative IHC staining of murine BM, spleen and liver for human CD45
antigen at week 6. Three mice from each group were sacrificed. Countable numbers of hCD45 +
cells were marked on each slide. (J) Quantitation of bioluminescence emitted from the whole
body of each mouse. Data represent the mean ± s.d. of each group. (K) Kaplan-Meier survival
curves of mice injected with luciferase-labeled OCI-AML3 cells (n = 7 per group; statistical
significance and median survival were evaluated using the log-rank test).
Data in bar/line graphs (B-F) represent the means of triplicate experiments with error bars
indicating SD. **P < 0.01, ***P < 0.001 as determined by two-tailed unpaired Student’s t-test.
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Figure S3.3

Figure S3.3 related to Figure 3.3. MCL-1 inhibition overcomes inherent ABT resistance in
OCI-AML3 cells.
(A) Representative flow cytometry plots of OCI-AML3 cells treated with MCL-1 antagonist A1210477 (5 μM) in the presence or absence of ABT (1 μM) for 24 h. (B) The cell numbers were
enumerated by flow analysis using CountBright counting beads and normalized to untreated
control. Data represent the means of triplicate experiments. P values were calculated by twotailed unpaired Student’s t-test. *** P < 0.001. Error bars, mean ± SD.

58

3.3.4 p53 Activation Induces Pro-Apoptotic Proteins and Reverses ABT–Induced
Upregulation of MCL-1
We next sought to address the mechanism by which p53 activation overcame
MCL-1–mediated resistance to BCL-2 inhibition. We chose OCI-AML3 for the
mechanistic studies because it is not only resistant to BCL-2 inhibitor ABT but also
relatively resistant to p53 activator RG (Figure S3.1A). p53 activation by RG
significantly increased mRNA levels of p53 target genes MDM2, BBC3, BAX and BAK
(Figure 3.4A). Similarly, kinetic study using immunoblotting revealed a rapid and strong
upregulation of MDM2 and Puma (Figure 3.4B) and a delayed upregulation of Bax and
Bak. These observations correspond with previous reports that p53 has lower affinity
for BAX/BAK promoters than for MDM2/BBC3 promoters
Bak each binds and counteracts MCL-1

4,9,

42,80.

Since Puma, Bax, and

their upregulation can contribute to

overcoming MCL-1–mediated resistance.
Although OCI-AML3 cells express a high level of MCL-1, MCL-1 was further
upregulated (2-fold) in these cells after acute ABT exposure (Figure 3.4C), which
could further enhance resistance to ABT. In contrast, p53 activation by RG induced a
time- and dose-dependent downregulation of MCL-1 (Figure 3.4C). The downregulation
occurred within 9 h, when no cleavage of PARP-1 was detected and the cell viability
was over 97%, excluding the possibility that MCL-1 degradation was a secondary
consequence of apoptosis. Moreover, BCL-2 inhibitor ABT quickly upregulated MCL-1
within a few hours, even in the presence of p53 activator RG, but the MCL-1
upregulation could be reversed later by p53 activation (Figure S3.4A). Notably, BCL-2
levels were not affected by ABT or RG treatment (Figure S3.4B). These findings
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indicate that p53 activation by RG could reduce MCL-1 levels and reverse ABTmediated upregulation of MCL-1.
3.3.5 p53 Activation Inhibits pERK and Activates GSK3 to Modulate MCL-1
Phosphorylation
To determine the mechanism underlying the reduction of MCL-1, we first conducted
qRT-PCR analysis, which indicated that p53 activation did not significantly affect MCL1
transcription (Figure 3.4D, lower panel). We postulated that MCL-1 might be regulated
by post-translational modifications (PTMs) that affect its stability. The bestcharacterized MCL-1 PTMs are phosphorylation at threonine 163 (T163) and serine
159 (S159)

28,81.

T163 phosphorylation (denoted as pMCL-1T) stabilizes MCL-1 but

also primes MCL-1 to be further phosphorylated at S159. The dually phosphorylated
MCL-1 (pMCL-1T/S) will be ubiquitinated and targeted for proteasomal degradation
28,81.

Consistent with a PTM mode of regulation, p53 activation by RG decreased pMCL1T and increased pMCL-1T/S (Figure 3.4E, lane 2), while BCL-2 inhibitor ABT
dramatically elevated pMCL-1T (Figure 3.4E, lane 3). Interestingly, p53 activation
converted the abundant stabilizing pMCL-1T to destabilizing pMCL-1T/S (Figure 3.4E,
lanes 3,4), which could explain how RG reversed ABT-induced upregulation of MCL-1.
In contrast, p53 knockdown upregulated pMCL-1T (Figure 3.4F, lane 2) and diminished
the ability of RG to convert pMCL-1T to pMCL-1T/S (Figure 3.4F, lanes 3,4),
suggesting an indispensable role of p53 in this conversion. The next question was
which kinase phosphorylated MCL-1 at T163 or S159 in this context.
pERK and pJNK have been reported to phosphorylate MCL-1 at T163

28,81,82.

It

appeared that pJNK did not play a major role here since neither pJNK nor total JNK
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levels decreased in response to p53 activation (Figure S3.4C). In contrast, p53
activation decreased pERK and pMCL-1T (Figure 3.4E), whereas p53 knockdown
simultaneously increased the two phospho-proteins (Figure 3.4F). Moreover,
suppressing pERK with the MEK-specific inhibitor PD0325901 (PD) eliminated both
pERK and pMCL-1T (Figure 3.4H). Collectively, these results indicate that pERK,
rather than pJNK, regulated MCL-1 phosphorylation at T163 in response to p53
activation or p53 knockdown.
GSK3 has been reported to associate with pMCL-1T and phosphorylate its S159
residue

81,83.

GSK3 protein is constitutively active, but its activity is diminished by

inhibitory phosphorylation at serine 9/21

83,84.

We found that p53 activation reduced

pGSK3 (Figure 3.4E, lane 2) but not total GSK3 (Figure S3.4E), implying a larger
fraction of active GSK3, which likely transformed ABT-induced pMCL-1T to a high level
of pMCL-1T/S (Figure 3.4E, lane 4). In contrast, p53 knockdown increased GSK3
phosphorylation and restrained GSK3 to transform pMCL-1T to pMCL-1T/S (Figure
3.4F, lane 2). To further verify GSK3’s role in this conversion, we pretreated OCI-AML3
cells with GSK3 inhibitor CHIR-99021 (CHIR, Figure 3.4J). Since little pMCL-1T was
present in untreated cells, BCL-2 inhibitor ABT was added to increase pMCL-1T (GSK3
substrate). ABT alone induced abundant pMCL-1T but not pMCL-1T/S (Figure 3.4E,
lane 3), implying that active GSK3 was probably present at a low level. Therefore p53
activator RG or MEK inhibitor PD was also added to release GSK3 activity (explained
in the next paragraph). As expected, ABT-PD or ABT-RG combinations induced
abundant pMCL-1T/S, while GSK3 inhibitor CHIR prevented the generation of
destabilizing pMCL-1T/S and increased MCL-1 levels (Figure 3.4J). These findings
indicate that GSK3 phosphorylated MCL-1 at S159 to promote MCL-1 degradation in
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Figure 3.4

Figure 3.4 p53 negatively regulates N-Ras and downstream MAPK/GSK3 signaling to
modulate MCL-1 phosphorylation and degradation.
(A) Relative mRNA expression of MDM2, BAX, BAK and BBC3 (Puma-encoding gene) in OCIAML3 cells after 12 h treatment with 1 μM RG. (B) p53 activation by RG induced timedependent upregulation of Puma, Bax and Bak but not Noxa in OCI-AML3 cells. (C) ABT
treatment (24 h) upregulated MCL-1 whereas RG treatment reduced MCL-1 in OCI-AML3 cells.
(D) Relative mRNA expression of MCL1 in OCI-AML3 cells after incubation with 1 μM ABT or
RG for 12 h. (E) Immunoblot of OCI-AML3 cells treated with vehicle, 1 μM RG, 1 μM ABT or
the combination for 24 h. The pMCL-1T and pMCL-1T/S antibodies recognize their epitopes in
a mutually exclusive manner. (F) Immunoblot of OCI-AML3 cells (control or p53 knockdown)
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treated with vehicle or 1 μM RG for 24 h. (G) 3D cylinder charts showing protein levels in
panels E & F as measured by quantitative immunoblot using the Odyssey Infrared Imaging
System. Value = 1 for untreated control. (H) OCI-AML3 cells were treated with vehicle, 100 nM
PD0325901 (PD, MEK inhibitor), 1 μM ABT or the PD-ABT combination for 12 h. (I) OCI-AML3
cells were treated with vehicle, 1 μM MK-2206 (MK, AKT inhibitor), 1 μM ABT or the MK-ABT
combination for 12 h. (J) GSK3 inhibition prevented the generation of pMCL-1T/S and
increased MCL-1. OCI-AML3 cells were treated for 24 h with different combinations of 1 μM
ABT, 100 nM PD, 1 μM CHIR-99021 (CHIR, GSK3 inhibitor) and 1 μM RG. (K) p53 activation
by RG reduced N-Ras and the Ras/Raf/MEK/ERK signaling cascade. OCI-AML3 cells were
treated with escalating doses of RG for 24 h. (L) Schematic diagram of the proposed
mechanism by which p53 activation overcame MCL-1–mediated resistance to ABT.

Figure S3.4

Figure S3.4 related to Figure 3.4.
(A) ABT-199 quickly induced MCL-1 upregulation in the absence or presence of RG, which
could be latter reversed by RG-induced p53 activation. OCI-AML3 cells were treated with
vehicle, 1 μM ABT, 1μM RG or the combination for indicated time. (B) BCL-2 inhibition by ABT,
p53 activation by RG or p53 knockdown did not affect BCL-2 protein expression. The loading
control immunoblots were the same as in Figure 4C and 4F. (C) RG or ABT did not change the
levels of active pJNK or total JNK. Cell lysates are the same as in Figure 4E. (D) p53
knockdown or p53 activation did not significantly affect pAKT level. p53 and β-actin
immunoblots are the same as in Figure 4F. (E) p53 activation by RG did not affect the
expression of total GSK3 or total ERK, but reduced pERK and pGSK3 as shown in Figure 4E.
The immunoblot for loading control is the same as in Figure 4E. (F) p53 knockdown did not
affect the expression of total GSK3 or total ERK, but increased pERK and pGSK3 as shown in
Figure 4F. (G) Immunoblot of MCL-1–overexpressing MOLM-13 cells treated with vehicle, 1 μM
ABT, 1 μM RG or the combination for 24 h. The results are consistent with our findings in OCIAML3 cells.
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this system.
3.3.6 p53 Downregulates N-Ras and Downstream MAPK Signaling and Releases
GSK3 Activity
To determine the mechanism by which p53 activation regulates GSK3 activity, we
first measured the effects of p53 expression on AKT, which is widely known to
phosphorylate and inactivate GSK3

83,84.

In OCI-AML3 cells, however, p53 knockdown

or p53 activation did not significantly affect the pAKT levels (Figure S3.4D). Meanwhile,
MK-2206, a selective AKT inhibitor, dramatically decreased pAKT, but only marginally
decreased pGSK3 and failed to release GSK3 activity to convert ABT-induced pMCL1T to pMCL-1T/S (Figure 3.4I), suggesting that AKT did not play a significant role here.
We next examined the MEK/ERK signaling, which has also been implicated in
regulating GSK3 inhibitory phosphorylation

84,85.

p53 activation by RG decreased

pGSK3 together with pMEK and pERK, (Figures 3.4E and 3.4K), whereas p53
knockdown resulted in concurrent upregulation of these three phospho-proteins (Figure
3.4F). Furthermore, MEK inhibitor PD markedly reduced pGSK3 (Figure 3.4H) and
released GSK3 activity, which robustly converted ABT-induced pMCL-1T to pMCL-1T/S
(Figure 3.4H). These findings together implied that the MEK/ERK signaling mediated
the inhibitory phosphorylation of GSK3 in this context. Next, we tracked the
Ras/Raf/MEK/ERK pathway bottom-up and unexpectedly found that p53 activation
downregulated the N-Ras protein levels (Figure 3.4E). Importantly, p53 knockdown
upregulated N-Ras levels (Figure 3.4F), while p53 activator RG induced a dosedependent decrease of N-Ras (Figure 3.4K). These results indicate that p53 could
negatively modulate N-Ras expression. It is well established that activation of
oncogenic Ras proteins can elevate p53 expression and p53 activity through the ARF-
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p53 circuit

86,87.

Our finding that p53 negatively regulated N-Ras protein levels,

identifies a previously unknown connection between p53 and N-Ras. The mechanism
through which this is accomplished needs to be defined in future studies. We also
quantitated and normalized the levels of proteins involved in this regulatory cascade
using Odyssey Infrared Imaging System and the companion software (see
Experimental Procedures), and generated two cylinder charts (Figure 3.4G)
corresponding to Figures 3.4E and 3.4F. The cylinder charts demonstrate similar trends
between the N-Ras/B-Raf/MEK/ERK signaling cascade and MCL-1 protein levels but
opposite trends between p53 and MCL-1 levels, or between p53 levels and the MAPK
signaling cascade. These correlations are consistent with our proposed mechanism.
The findings of these mechanistic studies can be briefly summarized as follows (also
summarized in Figure 3.4L). RG mediates activation of p53, which negatively regulates
the N-Ras/B-Raf/MEK/ERK pathway and releases GSK3 activity. Active GSK3 then
converts ABT-induced stabilizing pMCL-1T to pMCL-1T/S and promotes MCL-1
degradation. Meanwhile, p53 also induces Puma, Bax, and Bak to counteract the
remaining MCL-1, thus overcoming MCL-1–mediated resistance to BCL-2 inhibition at
multiple levels.
3.3.7 BCL-2 Inhibition Reciprocally Overcomes Resistance to p53 Activation by
Switching Cellular Response from Pro-Survival G1 Arrest to Apoptosis
RG induced comparable levels of p53 in MV-4-11, MOLM-13, and OCI-AML3 cells,
but substantially less apoptosis occurred in OCI-AML3 cells (Figure 3.5A), suggesting
that OCI-AML3 is relatively resistant to apoptosis induction by p53 and has a higher
apoptotic threshold. We postulated that if p53 level was not sufficient to push OCIAML3 cells across the apoptotic threshold, p53 might induce abundant p21 proteins to
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trigger pro-survival cell cycle arrest (CCA). Indeed, p53 activation by RG induced little
apoptosis in OCI-AML3 cells (Figure 5A) but robustly elevated p21 expression at
mRNA and protein levels (Figures 3.5B-C) and triggered CCA at G1 phase (Figure
S3.5A). The induced CCA was reversible as OCI-AML3 cells resumed proliferation
after removal of RG (Figure 3.5D). Moreover, p21 knockdown (Figure 3.5E) reduced
CCA at G1 phase (Figure S3.5A) but significantly increased RG-induced apoptosis
(Figure 3.5F). It has been well established that p21 can suppress tumors by inhibiting
cell proliferation. Our findings here indicate that p21 can also mediate tumor resistance
by protecting cancer cells from p53-induced apoptosis and by promoting reversible G1
arrest.
The apoptotic threshold can be directly modulated up or down by BCL-2 family
proteins. OCI-AML3 expresses high levels of BCL-2 and MCL-1, which contribute to its
high apoptotic threshold. Unlike MCL-1, BCL-2 protein levels were not affected by p53
activation or knockdown (Figure S3.4B). Although MCL-1 levels decreased upon p53
activation, the high levels of BCL-2 could still be sufficient to keep most cells below
apoptotic threshold (We previously demonstrated that knockdown of MCL-1 by 85% did
not significantly affect OCI-AML3 viability or proliferation

11,79.

Under this scenario, cells

would preferentially enter G1 arrest in response to p53-induced high levels of p21,
rather than undergo apoptosis. Based on these, we proposed that lowering the
apoptotic threshold by BCL-2 inhibition might be sufficient to switch the cellular
response of p53 activation from pro-survival G1 arrest to apoptotic cell death, thus
overcoming apoptosis resistance to p53 activation. To test this hypothesis, we
developed a protocol to simultaneously analyze apoptosis (AnnV +) and cell cycle
distribution of AnnV- live cells (Figure 3.5G). Unlike other commonly used methods, this
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Figure 3.5

Figure 3.5 BCL-2 inhibition reciprocally overcomes resistance to p53 activation via
shifting cellular response from G1 arrest to apoptosis.
(A) OCI-AML3 cells are relatively resistant to RG compared to MV-4-11 and MOLM-13 cells.
(B) Relative mRNA expression of CDKN1A (p21-encoding gene) in OCI-AML3 cells after 12 h
treatment with 1 μM RG. (C) Immunoblot showing p21 upregulation in OCI-AML3 cells after RG
treatment. (D) OCI-AML3 cells resumed exponential proliferation after removal of RG. OCIAML3 cells were treated with 1 μM RG7388 which was washed off after 24 h. The cell numbers
and viability were determined by Vi-CELL viability analyzer (Trypan blue exclusion assay).(E)
Immunoblots showing stable p21 knockdown in OCI-AML3 cells. Because of the low basal
expression of p53/p21, the control (shC) or knockdown cells were treated with 1 μM RG for 24
h prior to immunoblot analysis. (F) p21 knockdown significantly increased RG-induced
apoptosis (48 h treatment). (G) Flow cytometry plots showing the gating strategy used to
simultaneously analyze apoptosis and cell cycle distribution. The absolute cell numbers were
also enumerated with CountBright counting beads. (H) Representative flow cytometry plots of
OCI-AML3 cells after indicated treatments for 24 h. The gating was as depicted as in middle
panels of Figure 3.5G. (I) Apoptosis and cell cycle analysis of OCI-AML3 cells treated with RG
in the absence or presence of ABT for 24 h. The gating was the same as in Figure 3.5G. (J)
OCI-AML3 cells were treated with DMSO, 1 μM RG, 1 μM ABT or the combination for 24 h.
Data in line/bar graphs represent the means of triplicate experiments. Error bars, mean ± SD.
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Figure S3.5

Figure S3.5 related to Figure 3.5.
(A) p21 knockdown attenuated cell cycle arrest at G1 phase. OCI-AML3 cells were treated with
RG for 24 h, and then pulsed with 10 μM Edu for 1 h. Next the cells was fixed, permeabilized,
stained with Click-iT Plus reaction cocktail (Life Technologies) and analyzed by flow cytometry
according to the manufacturer’s instruction. (B) p21 knockdown reduced the numbers of live
cells (AnnV−/PI−) after 48 h treatment with indicated concentrations of RG.
Data represent the means of triplicate experiments. Error bars, mean ± SD.
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protocol avoided the interference of apoptotic cells in mitotic phase analysis. Counting
beads were also added to quantify cell numbers in different phases. As shown in
Figures 3.5H-I, p53 activator RG triggered little apoptosis but arrested most cells in G1
phase. Although BCL-2 inhibitor ABT did not affect cell cycle distribution, lowering the
apoptotic threshold by ABT substantially reduced G1-arrested cells and augmented
apoptosis induction by RG (Figures 3.5H-I). Moreover, adding ABT to RG markedly
increased cleavage of caspase-9, caspase-3, and PARP-1 (markers of apoptosis,
Figure 3.5J), which further supported our hypothesis that BCL-2 inhibition could
overcome resistance to p53 activation via switching cellular response from pro-survival
G1 arrest to apoptosis.
3.3.8 p53 Activation and BCL-2 Inhibition Reciprocally Overcome Resistance of
Primary AML Cells
p53 activator RG effectively induced dose-dependent apoptosis and reduced live
cell numbers in p53wt patient samples (7/7 tested, Figure 3.6A). Consistent with the
results in cell lines, RG could overcome ABT resistance in p53 wt but not in p53 deficient
primary AML cells (Figure 3.6B). Notably, one p53wt primary sample was highly
resistant to both ABT and RG as 48 h treatment with up to 1 μM of either compound
only induced marginal increase in apoptosis (Figure 3.6B, middle panels). Nonetheless,
the combination markedly increased apoptosis and reduced live cell numbers than
either treatment alone.
To further test the combination in a patient-derived xenograft (PDX) model, we
injected one resistant patient sample (p53wt) into NSG mice, which could rapidly kill
injected mice within few weeks (Figure 3.6C for experimental design). To gauge the
level of engraftment, we sacrificed one extra group of three mice 10 days post-injection
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Figure 3.6

Figure 3.6 BCL-2 inhibition and p53 activation reciprocally overcome drug resistance of
AML primary samples in vitro and in a PDX mouse model of resistance.
(A) Dose-dependent induction of apoptosis and reduction of live cell numbers by RG in p53 wt
primary AML samples (48 h treatment). PB, peripheral blood.(B) Representative ABT-resistant
primary samples with wild type or mutant p53 treated with ABT, RG or ABT-RG combination for
48 h. (C) Schematic outline of the PDX mouse model of drug resistance. (D) Representative
flow cytometry plot showing engraftment of human AML cells (hCD45+) in murine femur BM
(day 0). (E) Percentage of hCD45+ leukemic cells in murine BM, confirming leukemia
engraftment. The percentage of hCD45+ cells was calculated as: % hCD45+ cells = the number
of hCD45+ cells/the sum of hCD45+ and mCD45+ cells. (F) Flow cytometry analysis of hCD45+
leukemic cells in femur BM on day 28. Three mice from each group were sacrificed on day 28.
(G) Percentage of hCD45+ cells in femur BM on day 28. (H) Representative murine spleens
from sacrificed mice on day 28. (I) Kaplan-Meier survival curves of mice engrafted with
resistant primary AML cells (n = 7 per group; statistical significance was evaluated using the
log-rank test. NS, not significant.)
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and found that the BM (3/3) was uniformly engrafted with ~5% human CD45 + cells
(Figures 3.6D-E). The treatment was then initiated as described above. After 4 weeks,
three mice from each group were euthanized and examined. As shown in Figures 3.6FG, BM from control, ABT or RG groups was heavily infiltrated with leukemic cells
(>85% by flow cytometry analysis). Remarkably, the ABT-RG combination reduced
leukemic cells to 0.16% in the BM of one mouse and to undetectable levels in the other
two (Figure 3.6F). ABT or RG monotherapy slightly or moderately decreased spleen
size, whereas the combination dramatically reduced spleen size (Figure 3.6H). BCL-2
inhibitor ABT extended median survival by only 2 days, but combining ABT with p53
activator RG substantially prolonged mouse survival by 99 d (a 3-fold extension relative
to RG monotherapy, Figure 3.6I). Collectively, these in vitro and in vivo data indicate
that the combination of BCL-2 inhibition and p53 activation (ABT-RG) could
cooperatively overcome apoptosis resistance to either treatment alone in primary AML
cells. In the three different types of ABT-resistant mouse models (Figures 3.2D, 3.3G,
and 3.6C), p53 activator RG moderately prolonged mouse survival and reduced
leukemic burden, suggesting that the three different types of engrafted cells were also
relatively resistant to p53 activation. BCL-2 inhibitor ABT by itself prolonged mouse
survival only marginally or not at all. Nonetheless, combining ABT with RG extended
median survival at least 3-fold compared to RG alone in all three resistant mouse
models. These in vivo data, together with our in vitro results and mechanistic studies,
demonstrate that BCL-2 inhibition and p53 activation can reciprocally overcome
apoptosis resistance to either strategy alone and induce synthetic lethality of resistant
leukemia cells.
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Chapter 4 Discussion and Future Directions

__________________________________
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4.1 Discussion
Relapsed AML is a difficult cancer to treat effectively; therefore, there is a need for
improved treatment options for refractory AML. In Chapter 2, we demonstrate that
selective inhibition of BCL-2 by ABT-199 kills AML cell lines and primary patient cells
both ex vivo and in in vivo mouse xenografts as a single agent. The concentrations
used in our studies here are in the 0.001-1 µg/ml range, a range readily achievable in
clinical trials where serum concentrations of 3-4 µg/ml have been observed. Moreover,
the drug acts very quickly in vitro, killing cells within 2 hours of drug exposure. We also
show that ABT-199 functions on-target at the mitochondria. This is consistent with the
observation that AML myeloblasts from chemorefractory patients showed no difference
in their BCL-2 dependence, as measured by BH3 profiling, or sensitivity to ABT-199
compared to chemosensitive cells62.
Our in vitro results suggest there will be heterogeneity in clinical response (IC50s
ranged from 0.43 to >1000 nm), so that a predictive biomarker would be of great utility.
In Chapter 2, we present four methods that may be predictive of clinical response to
ABT-199. The first method is cytogenetics. The cellular death response to ABT-199
appears to be largely independent of cytogenetic and genetic mutation status, except
perhaps for complex karyotype and JAK2 mutant patients, suggesting that treatment
with ABT-199 could be useful for patients who have poor prognostic factors. The utility
of cytogenetics as a more general predictive biomarker for response to ABT-199 needs
to be examined across many more samples.
A second method is ex vivo short term culture of the primary patient samples with
ABT-199. The disadvantage of this method is that it is difficult to reliably culture primary
AML cells for the requisite time frame to observe cell death. We observed that even
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after a short 8 h culture there could be upwards of 60% spontaneous apoptotic death in
the control un-treated primary AML cells. Therefore, it would not be ideal to rely on an
in vitro cell death assay where many samples could be potentially lost due to
spontaneous cell death during culture.
The third predictive biomarker method is to measure BCL-2 levels by Western blot.
We show that increased expression of BCL-2 is associated with increased sensitivity to
ABT-199. However, given the complex interactions of the BCL-2 family members,
individual measurements of the various anti-apoptotics alone may not provide accurate
data on the in vivo biology of the anti-apoptotic dependencies in AML. Many of the
BCL-2 family members are regulated by post-translational modifications and
interactions with other proteins. These types of interactions are difficult to capture in
static Western blot measurements.
The fourth method, BH3 profiling, may prove useful as a predictive biomarker. BH3
profiling is a functional assay that accounts for the relative amounts and interactions of
all of the BCL-2 family members. We show here that the mitochondrial response to the
BAD peptide correlates with mitochondrial response to ex vivo ABT-199 treatment.
Most significantly, BH3 profiling could discriminate in vivo sensitivity of human AML
cells to ABT-199 (Figure 2.6). Thus, we may be able to use BH3 profiling of pretreatment AML samples to direct ABT-199 treatment to AML cases that are most BCL-2
dependent. While the assay is less familiar to many, it is a straightforward protocol
using reagents and equipment available in most clinical and research laboratories.
Moreover, results are available the same day the sample is acquired. As for the other
putative biomarkers, empiric testing in the clinical setting is the only way to truly
validate BH3 profiling as a useful predictive biomarker.
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BCL-2 was discovered in lymphoid cancer cells, and much of the research on this
protein has been conducted in lymphoid cells, where it is highly expressed 88. It is
therefore understandable that clinical testing of ABT-199 has so far focused on
lymphomas and CLL. In Chapter 2, we demonstrate that selective, on-target BCL-2
inhibition using a clinically active drug is a promising avenue for clinical investigation in
the myeloid malignancy AML. It is particularly important to recognize that even AML
myeloblasts that are resistant to conventional therapies appear to be quite sensitive to
BCL-2 inhibition. Thus, BCL-2 inhibition by ABT-199 offers hope to those AML cases
that most need novel therapeutic intervention. Our results in Chapter 2 strongly support
the testing of ABT-199 for treatment of AML patients as the majority of patient samples
were sensitive to the drug in ex vivo culture. Furthermore, our results support the
testing of BH3-profiling as a predictive biomarker for ABT-199 response in the clinic.
Based on this study, a multi-center phase II trial has been conducted to treat
relapsed and refractory AML patients or patients unfit for intensive chemotherapy. The
overall complete response rate was 19%; an additional 19% of patients demonstrated
antileukemic activity not meeting IWG criteria (partial bone marrow response and
incomplete hematologic recovery). 38% patients had isocitrate dehydrogenase 1/2
mutations, of which 33% achieved complete response or complete response with
incomplete blood count recovery. The BCL-2 inhibitor ABT-199 demonstrated its
activity and tolerable safety profile. Our preclinical and clinical findings provide a
compelling rationale to evaluate ABT-199 combined with other agents in AML.
In these clinical and preclinical studies, we identified MCL-1 expression confers
resistance to ABT-199. p53 is a critical apoptosis regulator which potentially induce
pro-apoptotic proteins such as Puma, Noxa, Bax to counteract MCL-1. In Chapter 3, we
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studied whether p53 activation could overcome MCL-1-mediated resistance to BCL-2
inhibitor ABT-199. We found that p53 activation combined with BCL-2 inhibition
achieved impressive anti-leukemia efficacy in vitro and in vivo. The combination of p53
activator RG and BCL-2 inhibitor ABT overcame resistance to either treatment alone,
and it remarkably prolonged survival in three AML mouse models of resistance. These
encouraging results provided the rationale for a multi-center phase II clinical trial in
AML (NCT02670044). If this combination therapy is proven successful in the clinic, this
concept is not limited to AML. Other hematological malignancies such as MDS, MM,
ALL, CML, and CLL also have low p53 mutation rates and express high levels of BCL-2.
These p53wt malignancies may respond as well to the proposed combination strategy.
Additionally, several compounds have been reported to promote proper folding of
mutant p53 and restore its transcriptional function8,89. Combining these compounds
with BCL-2 inhibitors might represent a promising direction for p53 mutant cancers. We
also found that low doses of ABT-RG combination synergized well with cytarabine and
idarubicin (Figure 4.1), revealing its potential to be combined with AML front-line
therapeutics.
Anti-apoptotic MCL-1 has been increasingly recognized as an important target in
cancer therapy4,9,33. MCL-1 protein has a short half-life and it can be cleaved by
activated caspases during apoptotic cell death81. A number of studies observed MCL-1
reduction after treatment with different anti-tumor therapeutics; but the MCL-1 decrease
was often accompanied by a substantial level of apoptosis. Therefore, it is ambiguous
whether the observed MCL-1 decrease was the cause of apoptosis or merely a
secondary consequence of apoptosis, especially when mechanistic insights were
lacking in the majority of these reports. In the current study, (1) we observed that p53
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Figure 4.1

Figure 4.1 Low doses of ABT-RG combination synergizes with idarubicin, cytarabine and
sorafinib.
(A-C) MV-4-11, MOLM-13 and OCI-AML3 cells were treated with indicated compounds or combinations
for 48 h (ABT-RG, 1:1 ratio). Data in bar/line graphs represent the means of triplicate experiments. Error
bars, mean ± SD. (D) TP53 and FLT3 status of the three AML cell lines.
Data in panels A-D represent the means of triplicate experiments. Error bars, mean ± SD.
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activator RG induced MCL-1 reduction prior to apoptotic cell death; (2) p53 knockdown
upregulated MCL-1 while both the control and knockdown cells were highly viable, thus
excluding potential interference from apoptosis; (3) Moreover, we illustrated the
underlying mechanism that p53 activation regulated N-Ras/B-Raf/MEK/ERK/GSK3
signaling to modulate MCL-1 phosphorylation and promote MCL-1 degradation. These
points collectively support the negative regulation of MCL-1 by p53 and exclude the
possibility that the observed MCL-1 reduction is merely a consequence of apoptosis.
To validate our mechanistic findings in another system, we also ectopically
overexpressed MCL-1 in MOLM-13 cells to make them resistant to BCL-2 inhibitor ABT
(Figures S3.2A and S3.2C). As in OCI-AML3 cells, p53 activator RG reduced MCL-1 in
MOLM-13_MCL-1 cells (Figure S3.4G, lane 3). Moreover, acute ABT exposure
similarly induced upregulation of MCL-1 and pMCL-1T (Figure S3.4G, lane 2), which
could be reversed by p53 activator RG (Figure S3.4G, lane 4). RG also decreased
pERK and pGSK3 (Figure S3.4G), resulting in an increase in active GSK3, which could
potentially

convert

pMCL-1T

to

pMCL-1T/S.

Indeed,

combination-treated

MOLM13_MCL-1 cells had much lower levels of pMCL-1T but higher levels of pMCL1T/S than ABT-treated cells (Figure S3.4G, lanes 2,4). These data are in line with and
support our mechanistic findings in OCI-AML3 cells.
Biological outcomes of p53 activation can be determined by different cellular
thresholds for CCA and apoptosis42,80,90. For tumor cells with high apoptotic threshold,
p53 activity might not induce enough pro-apoptotic proteins to push tumor cells through
their apoptotic threshold but may induce sufficient cell cycle regulatory proteins to
trigger reversible CCA. To minimize CCA-mediated resistance to p53 activation, we
proposed to convert the cellular response from CCA to apoptosis by reducing the
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apoptotic threshold with BCL-2 inhibitor ABT. Paradoxically, ABT induced an
unwelcome increase in MCL-1, which further raised the apoptotic threshold. Given that
a low dose of ABT (i.e., 10 nM) was sufficient to upregulate MCL-1 (Figure 3.4C),
special attention should be given to possible MCL-1 elevation when using ABT in the
laboratory or in the clinic. Nevertheless, in our study, the MCL-1 elevation can be
reversed by p53 activator RG. In this scenario, BCL-2 inhibition by ABT could
effectively reduce the apoptotic threshold and switch the outcome of p53 activation
from G1 arrest to apoptosis. In addition, others and we have shown that AML and other
hematologic malignancies widely overexpress BCL-211,91-93. This may explain why in
this study, BCL-2 inhibitor ABT almost always synergized with RG in p53 wt AML cell
lines, in p53wt primary samples, and in three resistance mouse models of AML.
In Chapter 3, we demonstrated that p53 activation could overcome inherent and
acquired resistance to BCL-2 inhibition by regulating the Ras/Raf/MEK/ERK/GSK3
signaling to promote MCL-1 degradation and by promoting the expression of proapoptotic proteins. In addition, BCL-2 inhibition reciprocally overcame apoptosis
resistance to p53 activation by shifting cellular response from G1 arrest to apoptosis.
The mechanistic studies, together with the remarkable in vitro and in vivo efficacy,
strongly support future research and clinical trials testing combinations of BCL-2
inhibitors with p53-reactivating compounds.

4.2 Future Directions and Unanswered Questions
4.2.1 To Systematically Study Mechanisms of Resistance to BCL-2 inhibitor ABT199
Directly targeting the apoptosis pathways might potentially minimize the emergence
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of acquired resistance mediated by the complex cancer signaling networks. However,
the BCL-2 family anti-apoptotic proteins (i.e., BCL-2, MCL-1, BCL-XL, BFL-1, and BCLW) are functionally redundant, at least in their functions to inhibit apoptotic cell death.
Thus, overexpression of other anti-apoptotic protein(s) could potentially render cancer
cells resistant to the BCL-2 selective inhibitor ABT-199. Indeed, in Chapter 2, we found
that AML cells with high basal levels of MCL-1 are inherently resistant to ABT-199.
Moreover, in Chapter 3, we found that initially sensitive AML cells could acquire
resistance to ABT-199 by upregulating MCL-1 after long-term exposure to this
compound. We also demonstrated that MCL-1 knockdown or Mcl-1 inhibition could resensitize these resistant AML cells to ABT-199, whereas MCL-1 overexpression
conferred resistance to ABT-199. These results collectively suggest the pivotal roles of
MCL-1 in mediating resistance to ABT-199 in this context. Of note, OCI-AML3, MOLM13 and MV-4-11 cells express relatively low basal levels of BCL-XL, BFL-1, and BCL-W
when compared to the levels of BCL-2 or MCL-1, these may explain why BCL-XL, BFL1, and BCL-W seemingly do not play a significant role in our study. However, BFL-1,
BCL-XL, or BCL-W might be potentially important and may mediate resistance to ABT199 in other systems such as cancer cells with high basal expression of these proteins.
It is also reasonable to speculate that sensitive cancer cells might acquire adaptive
resistance to ABT-199 by elevating the expression of BFL-1, BCL-XL or BCL-W.
Therefore, it will be of great interest to profile the expression changes of all BCL-2
family proteins in a large panel of cancer cell lines before and after exposure to ABT199, to systematically study mechanisms of resistance to ABT-199.
Another potential mechanism that could promote resistance to ABT-199 is
acquisition of mutations in BCL-2 protein. The BH1, BH2, and BH3 domains of BCL-2
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protein form a hydrophobic pocket to sequester Bax, Bak, and BH3-only proteins. BH3
mimetic ABT-199 can dock into this pocket to replace and release Bax, Bak, and BH3only proteins to promote apoptosis. If BCL-2 protein acquired mutations that cause the
conformational changes of the hydrophobic pocket to make it less accessible or less
avid for ABT-199, cancer cell lines with these Bcl-2 mutations could become resistant
to ABT-199. Mutation acquisition mediated resistance to ABT-199 has been reported in
mantle cell lymphoma cell lines after chronic exposure to this compound94. Of note, the
mutations in the BH3-binding pocket might also compromise the ability of BCL-2 to
sequester Bax, Bak, or BH3-only proteins and, therefore, may not confer cancer cells
survival advantages over cancer cells without these mutations. Based on this scenario,
mutation-mediated resistance to BH3 mimetics such as ABT-199 is less likely to
happen for BCL-2 anti-apoptotic proteins, when compared to many other cancer targets
that do not rely on protein interactions for their oncogenic functions. In the era of omics,
high-throughput techniques such as DNA-seq, RNA-seq, Reverse-Phase Protein
micro-array (RPPA), can be utilized to systemically investigate the mechanisms of
acquired resistance to ABT-199 by comparing the differences between the pre-treated
cancer cells and cancer cells with acquired resistance.
4.2.2 To Study Mechanisms of Acquired Resistance to the Combination of BCL-2
Inhibition and p53 Activation
In Chapter 3, we have shown that the concomitant BCL-2 inhibition by ABT-199
and p53 activation by RG7388 could mutually overcome resistance to either treatment
alone. As a result, the combination achieved remarkable efficacy in vitro and markedly
prolonged survival in three resistance models of AML. Although the observed efficacy
was impressive enough and actually exceeded our expectations, the combinatorial

81

treatment did not cure the mice. All mice eventually died of leukemia as manifested by
the high leukemic burden of dissected mice, indicating that the engrafted AML cells
eventually developed resistance to the combination therapy. It would be very intriguing
to study the mechanism of acquired resistance to the combined therapy. The
mechanistic findings from this proposed study could be of great significance as they
could help devise novel strategies to overcome the acquired resistance so that to
release the full potential of such combined therapy. Bearing this in mind, we have had
collected and preserved the AML cells from the mice in the control, ABT-199, RG7388,
and the combination groups. We are currently using high-throughput techniques such
as RNA-seq, Reverse-Phase Protein micro-array (RPPA), and DNA-seq to systemically
investigate mechanisms of acquired resistance to either monotherapy or to the
combination therapy.
4.2.3 To Illustrate the Underlying Mechanism by Which p53 Negatively Regulates
Ras
p53 is arguably the most important tumor suppressor protein, whereas Ras
proteins are among the most important oncogenes. Ras proteins are single-subunit
small GTPases, which function as binary signaling switches. When bound to GTP, Ras
is switched to the “on” state, which initiates downstream signaling cascade to regulate
diverse processes such as cell growth, survival, differentiation, and cell migration.
When bound to GDP, Ras is switched to the “off” state. H-Ras, K-Ras, and N-Ras are
three Ras protein variants in human cells. Mutations of H-, K-, and N-Ras have been
implicated in many types of cancers. Ras mutations that lead to constitutive activation
of Ras signaling are found in ~30% of all human tumors and up to 90% in certain types
of cancers, making Ras mutations the most common abnormality of all human proto-
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oncogenes.
It has been well documented that oncogenic Ras activation engages the ARF–p53
circuit to trigger p53 signaling. Our finding that p53 negatively regulates N-Ras at
protein levels, identifies a previously unknown connection between p53 and N-Ras.
The mechanism through which this is accomplished needs to be defined in future
studies and should be of great interest to the p53 and Ras communities. Other
intriguing questions are whether p53 also negatively regulates N-Ras in other types of
cancers and whether p53 also downregulates the expression of other Ras variants in
human, mouse, and other model systems.
4.2.4 To Study the Mechanism by Which ABT-199 Elevates MCL-1 Expression
In Chapter 3, we found that ABT-199, like its predecessor ABT-737, can induce
MCL-1 expression within few hours. Yecies, et al. reported that ABT-737 exposure
increased the expression of MCL-1 mRNA in lymphomas31. However, ABT-199
exposure did not elevate MCL-1 mRNA levels in our study (Figure 2.4D). We
postulated that MCL-1 might be regulated at post-translational levels. Indeed, we found
that ABT-199 treatment dramatically induced MCL-1 phosphorylation at Threonine 163,
a post-translational modification that stabilizes MCL-1. The MEK/ERK signaling has
been documented to promote MCL-1 phosphorylation at Threonine 163. Konopleva, et
al. reported that ABT-737 was able to activate MEK/ERK signaling to elevate MCL-1
levels95. In our current study with ABT-199, MEK/ERK signaling seemingly did not play
a significant role because neither pMEK/pERK nor total MEK/ERK was affected by
ABT-199 treatment. The detailed mechanism through which ABT-199 induced MCL-1
expression is beyond the scope of this study. Nevertheless, elucidating the underlying
mechanism shall be of great significance, as it would help devise strategies to
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circumvent the unwelcome elevation of MCL-1 that can be caused by even a low dose
of ABT-199.
4.2.5 To Test the BCL-2 Inhibition/p53 Activation Strategy in immunocompetent
Mice or in immunodeficient Mice with Humanized Immune System
For the mouse studies in Chapters 2 and 3, we injected AML cell lines or patient
samples intravenously into NOD SCID gamma (NSG) mice. After confirmation of AML
engraftment, the injected mice were treated with different therapeutic regimens. NSG
mice are a proven host for engraftment of hematopoietic malignancies as well as solid
tumors. The immunodeficient NSG mice combine the characteristics of the Non-obese
diabetic (NOD) background, the severe combined immune deficiency mutation (SCID)
background and the IL2 receptor gamma chain deficiency. As a result, NSG mice are
severely immune-deficient and don’t have mature T cells, B cells, or functional NK
cells. NSG mice are also deficient in cytokine signaling because of the deficiency of IL2
receptor gamma chain. These features facilitate the engraftment of human normal or
malignant cells, especially for engraftment of human hematopoietic cells and leukemia
cells. However, in vivo studies using NSG mice may neglect the potential effects of
innate and adaptive immunity in fighting cancer cells.
Accumulating pre-clinical and clinical evidence suggests that targeted therapies or
conventional chemotherapies not only induce direct cytotoxic/cytostatic effects, but also
stimulate immune responses to activate T, NK, and other immune cells to fight cancer
cells. Because NSG mice do not have functional immune system, the xenograft mouse
models in this study possibly underestimate the efficacy of our proposed combination
strategy. The roles of immune system in cancer therapies can be studied using
transgenic, syngeneic immunocompetent mouse models or immune-deficient mice with
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established human immunity following transplantation with hematopoietic stem cells or
peripheral blood mononuclear cells. The humanized mouse hosts recently become
commercially available, though expensive, from the Jackson Laboratory. These
immunocompetent

mouse

models

could

be

used

to

study

whether

an

immunocompetent background could further enhance the efficacy of combined BCL-2
inhibition and p53 activation.
4.2.6 To Study the Efficacy of Concurrent BCL-2 Inhibition and p53 Activation in
killing Leukemia Stem Cells (LSCs)
LSCs are at the top of the hierarchy of malignant hematopoiesis and possess the
ability to drive leukemogenesis in vivo96,97. LSCs are typically quiescent and resistant to
conventional chemotherapies and, as a result, potentially drive leukemia relapse after
initial responses72,98. Recent evidence suggests that most functionally defined chronic
myeloid leukemia LSCs have relatively low levels of reactive oxygen species and
aberrantly overexpress BCL-2 protein72. Furthermore, BCL-2–mediated oxidative
phosphorylation is reportedly essential for LSC energy homeostasis, such that BCL-2
inhibition reduces oxidative phosphorylation and selectively eradicates quiescent CML
LSCs72. Meanwhile, other published results have demonstrated that putative AML
LSCs express high levels of MCL-199 and MCL-1 suppression kills transformed AML
blast and stem cells, suggesting a critical role of MCL-1 for LSC survival28, though not
ruling out a concomitant requirement for BCL-2. Overall, it is still equivocal that whether
BCL-2, MCL-1 or both are critical for LSC survival.
In Chapter 3, we found that p53 activation by RG7388 promoted MCL-1
degradation and induced pro-apoptotic proteins to counteract the remaining MCL-1.
Base on this, it is reasonable to speculate that the combination of RG7388 and ABT-
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199 may be very effective in killing LSCs by combined inhibition of Mcl-1 and Bcl-2.
However, toxicity may be an issue when targeting proteins expressed in both leukemic
stem cells and hematopoietic stem cells. In this regard, Opferman and colleagues
reported that MCL-1 might play an essential role in the survival of murine hematopoietic
stem cells and early myeloid precursors63. In the same study, murine AML cells were
demonstrated to be more sensitive to MCL-1 deletion than normal hematopoietic stem
and progenitor cells63, suggesting that a therapeutic window might exist. Consistently,
we found that a pan-BCL-2 antagonist, which simultaneously inhibits BCL-2, MCL-1,
BCL-XL, and BFL-1 but with the highest affinity for MCL-1, killed most LSCs but were
well tolerated by hematopoietic stem and progenitor cells 79. Based on these, we
speculate that the combination of BCL-2 inhibition and p53 activation may effectively
kill LSCs while sparing the majority of normal hematopoietic stem and progenitor cells.
However, the conclusions can only be drawn from systematic pre-clinical or clinical
studies to evaluate the toxicity of such combined therapy on normal hematopoiesis.
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